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ABSTRACT 
BH3 mimetic compounds induce tumor cell death through targeted inhibition of anti-
apoptotic BCL2 proteins. Resistance to one such compound, ABT-737, is due to 
increased levels of anti-apoptotic MCL1. Using chemical and genetic approaches, we show 
that resistance to ABT-737 is abrogated by inhibition of the mitochondrial RING E3 
ligase, MARCH5. Mechanistically, this is due to increased expression of pro-apoptotic 
BCL2 family member, NOXA, and is associated with MARCH5 regulation of MCL1 
ubiquitination and stability in a NOXA-dependent manner. MARCH5 expression 
contributed to an 8-gene signature that correlates with sensitivity to the preclinical BH3 
mimetic, navitoclax. Furthermore, we observed a synthetic lethal interaction between 
MCL1 and MARCH5 in MCL1-dependent breast cancer cells.  Our data uncover a 
novel level at which the BCL2 family is regulated; furthermore, they suggest targeting 
MARCH5-dependent signaling will be an effective strategy for treatment of BH3 
mimetic-resistant tumors. 
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CHAPTER 1. INTRODUCTION 
Mitochondria regulate critical aspects of cellular function and homeostasis. Apart from 
generating energy required for cellular function, mitochondria also serve as major 
signaling hubs in pathways related to redox regulation, innate immune signaling, and 
apoptosis1,2. Mitochondria have also been implicated in retrograde signaling; during this 
process, metabolic changes are sensed by these organelles and relayed to the nucleus in 
order to mount a transcriptional response3. In line with these diverse functions, the 
mitochondrial outer membrane is equipped with numerous proteins that are required for 
processes such as energy conversion, transfer of metabolites, and membrane dynamics; all 
these processes are important for mediating signal transduction events. 
 
Mitochondria and Cancer 
As mitochondria are major cellular signaling platforms, their dysfunction plays a critical 
role in the etiology of diseases such as neurodegeneration, metabolic disorders, and 
cancer1,4. In cancer, virtually all tumors exhibit altered metabolic states. According to the 
theory put forward by Otto Warburg, cancer cells produce ATP through glycolysis even 
under aerobic conditions. In contrast, healthy cells generate energy from the oxidation of 
pyruvate, which is a glycolytic end-product that is oxidized within the mitochondria. 
According to Warburg, the switch from mitochondrial respiration to aerobic glycolysis, 
which may be due damaged or dysfunctional mitochondria, was a key driver of 
tumorigenesis5.  
 However, it is now clear that the switch to glycolysis is predominantly due to the 
reprogramming of mitochondrial metabolic pathways by activated oncogenes such as RAS, 
MYC, and AKT, rather than being a default consequence of mitochondrial defects.  
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These oncogenes also render cancer cells resistant to programmed cell death through 
rewiring of the mitochondrial apoptotic pathway. Thus, many cancer cells are refractory to 
chemotherapeutics due to increased dependency on pro-survival pathways and altered 
metabolism6–8. 
Apoptosis 
Apoptosis (or ‘programmed cell death’) is vital for the regulation of cell growth and 
maintenance of tissue homeostasis, and its evasion is one of the major hallmarks of 
cancer9,10. The reduced sensitivity of cancer cells to apoptosis is largely due to up 
regulation of anti-apoptotic genes and inactivation of genes crucial for mediating cell 
death. Characteristics of apoptosis include cell shrinkage, nuclear fragmentation, chromatin 
condensation and membrane blebbing, which are cumulatively mediated by a group of 
proteases called caspases11. The signaling cascades that lead to cell death are diverse and 
depend on the upstream death-inducing stimulus. The different categories of cell death 
pathways can be broadly categorized as follows- 
(i) Extrinsic Apoptosis 
The extrinsic apoptotic pathway initiates apoptosis through death receptors that are 
members of the tumor necrosis factor (TNF) receptor gene superfamily. These receptors 
transmit death-inducing signals from the cell surface to intracellular signaling pathways. 
Examples of ligands and corresponding death receptors include FasL/FasR, TNF-
α/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5. The binding of ligands to receptors 
initiates the recruitment of adapator molecules such as the FAS-associated death domain 
protein (FADD) that can in turn dimerize and activate the initiator caspase 8. This protease 
can in turn cleave its substrates BID and caspase 3 to initiate cell death11,12. 
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(ii) Intrinsic Apoptosis 
The intrinsic signaling pathway instigates apoptosis through non-receptor-mediated stimuli 
that converge on the mitochondria. This pathway is predominantly activated by “intrinsic 
stimuli” such as oncogene activation, growth factor withdrawal, and DNA damage, and is 
characterized by mitochondrial outer membrane permeabilization (MOMP), release of 
cytochrome C and the formation of a cytosolic apoptosome complex consisting of adapter 
protein apoptotic protease activating factor 1 (Apaf1) and the activating protease caspase 9. 
This complex in turn mediates the activation of the downstream effector caspases such as 
caspase 3. The proteolytic activity of the caspase proteins serves to cleave substrates such 
as nuclear lamins, ICAD/DFF45 (inhibitor of caspase activated DNase or DNA 
fragmentation factor 45) and PARP (poly-ADP ribose polymerase). These cleaved proteins 
induce DNA fragmentation, leading to cell death. In the absence of apoptotic stimuli, 
caspase activation is blocked by the X-linked inhibitor of apoptosis protein (XIAP) and the 
cellular inhibitors of apoptosis I and II (cIAP I, II). Upon initiation of MOMP, the release 
of second mitochondria-derived activator of caspase (SMAC/DIABLO) blocks XIAP -
mediated inhibition of caspase activity11,12.   
A great deal of cross talk exists between the extrinsic and intrinsic pathways. In certain 
types of cells (type I) extrinsic apoptosis involves the activation of the effector caspase 3 
by caspase 8. In other types of cells (type II), the cleavage of the BCL2 homology 3 
(BH3)-interacting domain death agonist (BID) and its subsequent activation can activate 
the intrinsic pathway leading to MOMP. The distinction between type I and II cells is 
dependent on the requirement of MOMP- dependent inhibition of XIAP in death receptor-
mediated apoptosis11,13.  
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Figure 1.1.  Extrinsic and Intrinsic Apoptotic Pathways                  
The extrinsic and instrinsic apoptotic pathways are activated by diverse stress 
stimuli. The binding of ligands to cell surface death receptors activates the extrinsic 
pathway. This involves the activation of caspase 8, which can directly activate 
caspase 3 leading to apoptosis or activate MOMP through the cleavage of BID.  
The intrinsic pathway is characterized by mitochondrial outer membrane 
permeabilization, release of cytochrome C and activation of a cytosolic apoptosome 
complex. This is turn leads to activation of downstream caspases 9 and 3 and cell 
death.         
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(iii) Alternate programmed cell death pathways 
Apart from the above “classical” apoptotic pathways, other forms of programmed of cell 
death related to necrosis have been recently described. Necrosis is an autolytic form of cell 
death characterized loss of cell membrane integrity and release of cellular contents. 
Traditionally thought of as an unregulated process, it is now apparent that necrotic cell 
death can also occur in a programmed manner14. These programmed forms of necrosis 
include processes such as necroptosis, ferroptosis, mitochondrial permeability transition 
(MPT)-dependent necrosis, pyroptosis and pyronecrosis. Of these, pyroptosis and 
necroptosis are the best characterized forms. Pyroptosis is induced by inflammasome 
activation and has important functions in host defense and inflammation. Necroptosis is 
mediated by the receptor interacting protein kinase-3 (RIPK3) and its substrate, mixed 
lineage kinase like (MLKL) and its dysregulation is implicated in the pathogenesis of 
many diseases related to chronic inflammation15,16. 
 
BCL-2 Family of Proteins 
(i) Classification of BCL-2 family proteins 
In addition to its suppression by IAPs, the initiation of MOMP and release of cytochrome 
C is tightly regulated by the B cell CLL/lymphoma-2(BCL2) family of proteins. This 
family consists of closely related proteins possessing different combinations of four BCL2 
homology (BH) domains and can be divided into three classes. The first class contains 
anti-apoptotic BCL-2 proteins (e.g. BCL2, BCLXL, and MCL1) that possess all four BH 
domains. The proteins interact with the BH3 domains of the pro-apoptotic BCL-2 effectors 
(e.g. BAK and BAX) which possess three BH domains, or with the pro-apoptotic BH3-
only domain proteins (e.g. NOXA, BIM, PUMA, and BAD)17,18.   
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BCL-2 family members also possess additional roles in non-apoptotic cells including 
maintenance of normal cell physiology, autophagy, calcium homeostasis, mitochondrial 
dynamics, and cellular energetics19. Both BCL2 and BCLXL interact with members of the 
mitochondrial fusion and fission machinery (MFN1/2 and DRP1, respectively) to regulate 
mitochondrial dynamics20. In addition, a relationship between mitochondrial fusion and 
BAX-dependent permeability transition pore formation has been described21,22.  
 
Figure 1.2. The BCL-2 Family of Proteins 
Schematic representation of BCL-2 family members classified as anti- or pro-
apoptotic, possessing different combinations of BH domains. 
 
(ii) Interactions between BCL-2 family members 
 Many specific functional interactions between the BCL2 family members have been 
described. Broadly speaking, interactions between the anti- and pro- apoptotic members 
dictate whether a cell lives or dies.  Under steady state conditions, the anti-apoptotic 
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members serve to inhibit the activity of the pro-apoptotic proteins. Upstream apoptotic 
stimuli induce conformational changes and alterations in the stoichiometry between pro- 
and anti- apoptotic proteins. The activated pro-death proteins such as BIM, PUMA, NOXA 
and BAD specifically interact with and inhibit BCL2, BCLXL and MCL1, to activate the 
downstream death signaling cascade18,23,24. 
 
Figure 1.3.  Specific interactions between pro- and anti- apoptotic proteins 
In response to apoptotic stimuli, the BH3-only proteins BIM, PUMA, NOXA and 
BAD (shown in orange) specifically inhibit anti-apoptotic proteins (shown in blue), 
thereby inducing cell death.  
 
Two models that explain regulation of the apoptotic switch have been described. First is 
the “director activation” model involves the BH3-only proteins such as BIM and PUMA, 
which directly engage and activate the pro-apoptotic effectors BAX and BAK. On the 
other hand, the indirect activator or “derepressor” model involves the binding of BH3-only 
proteins to pro-survival BCL-2 family members, which leads to the release of BH3-only 
activator proteins. In most cases, the apoptotic response is elicited by a combination of 
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events described in  both models25,26. However, there remain many unanswered questions 
regarding the way in which diverse apoptotic and stress stimuli govern these interactions, 
and whether other mitochondrial proteins have prominent roles in coordinating the 
apoptotic response. 
 
Figure 1.4. BCL-2 family interactions  
Two models of BAX and BAK activation have been described- the indirect 
activator and the direct activator–derepressor models. The indirect activator model 
proposes that BAX and BAK are bound and inhibited by anti-apoptotic BCL-2 
proteins, and that competitive interactions of activated BH3-only proteins with anti-
apoptotic BCL-2 family members is required to activate BAX and BAK. In the 
direct activator–derepressor model, BAX and BAK are activated through 
interactions with BH3-only proteins. These interactions are inhibited by the anti-
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apoptotic BCL-2 proteins, which sequester the activating BH3-only proteins or 
bind directly to BAX and BAK.  
 
Since the present study is focused on select BCL-2 family members, including NOXA, 
MCL1 and BCLXL, these proteins will be discussed in detail in the following sections. For 
an in-depth discussion of other family members, see Youle, Strasser., 200827. 
(iii) MCL1 anti-apoptotic protein 
The myeloid cell leukemia 1 (MCL1) protein was initially discovered as an immediate 
early gene expressed during PMA-induced differentiation of a myeloid leukemia cell line 
(ML-1)28. In addition, MCL1 is essential for embryonic development, hematopoiesis and 
lymphopoiesis29.  
MCL1 exerts its anti-apoptotic function through the sequestration of pro-apoptotic BAX 
and BAK and also through interactions with BH3-only proteins, which in turn prevents 
BAX/BAK activation26. 
MCL1 has the same three BH domains as those present in BCL2 and BCLXL, but differs 
from its anti-apoptotic counterparts in that is possesses a much longer N-terminal region.  
This region contains critical residues responsible for MCL1 function and turnover, 
including sites for ubiquitination and N-terminal processing events. In addition this region 
also contains numerous proline (P), glutamic acid (E), serine (S) and threonine (T) residues 
that collectively form the PEST domain, which is characteristic of short-lived proteins. 
MCL1 protein indeed possesses a short half-life, as confirmed through pulse chase 
experiments. Its stability is regulated primarily through post-translational events such as 
phosphorylation and ubiquitination. The PEST domain contains phosphorylation sites for 
JNK, ERK-1, and p38 MAPK kinases. Phosphorylation by these kinases stabilizes MCL1, 
thus conferring anti-apoptotic activity. Conversely, phosphorylation by the GSK3 kinase 
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can serve as a “priming” event for further post-translational modifications, such as 
ubiquitination and degradation of MCL1. This in prevents interactions of MCL1 with pro-
death proteins such as PUMA and BIM, thereby unleashing their apoptotic activity30,31. 
 
Figure 1.5.  Anti-apoptotic MCL1 
MCL1 possesses a long amino terminus consisting of numerous regulatory sites 
including residues important for phosphorylation (PEST), ubiquitination and N 
terminal processing.  
 
Although MCL1 abundance can be regulated at the transcriptional level depending on the 
availability of growth factors and cytokines, its turnover is mainly regulated post-
translationally through its ubiquitination. To date four E3 ubiquitin ligases have been 
identified that bind and target MCL1 for degradation. These are MULE, a HECT domain 
ubiquitin ligase, βTRCP and FBXW7, two SKP1-cullin-1-F-box (SCF) complex E3 
ligases, and TRIM17, an E3 ligase implicated in the ubiquitination and degradation of 
MCL1 in neurons32,33,34. The ubiquitination by βTRCP, FBXW7, and TRIM17 relies on the 
phosphorylation sites present in the long unstructured N-terminal region of MCL1. This 
region contains the PEST-associated phosphodegron sites (i.e., the phosphorylation sites 
for the JNK, ERK and GSK3 kinases) that control the access of the E3 ligases to MCL131. 
MCL1 stability is also controlled by the deubiquitinase, USP9X. After USP9X binds 
MCL1, USP9X removes the Lys 48-linked polyubiquitin chains that mark MCL1 for 
proteasomal degradation35.  
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MCL1 expression is often dysregulated in cancer. For example, many solid and 
haematological malignancies harbor extra copies of the MCL1 gene, with MCL1 being 
amplified in up to 10.9% of all samples analyzed. Amplification frequency was especially 
high in lung and breast cancers36,37. In addition, cancer cells also exploit the ubiquitin 
proteasome system responsible for MCL1 turnover. This occurs via MCL1 E3 ubiquitin 
ligases, increased levels of MCL1 deubiquitinases or through modification of MCL1 itself. 
Consequently, this leads to reduced turnover rate and increased stability of MCL1 
protein33,35. 
 
Upregulation of MCL1 renders cancers refractory to chemotherapeutic-induced cell death.  
Apart from its anti-apoptotic role at the mitochondrial outer membrane, recent studies have 
shown that MCL1 can also localize to the mitochondrial matrix and regulate mitochondrial 
fusion and respiration38. Thus, it appears that MCL1 is a critical regulator of diverse 
mitochondrial signaling pathways.  An in depth understanding of MCL1 function and the 
pathways that regulate its stability and activity would provide insight into targeting MCL1 
for therapeutic purposes. In principle, MCL1 could be inhibited by accelerating its 
degradation or by functional antagonism that would relieve MCL1’s inhibitory activity 
toward pro-apoptotic proteins.  
 
(iv) NOXA 
Intriguingly, as was the case for MCL1, NOXA or PMAIP1, was initially described as a 
PMA-induced gene39. It was later defined as a p53 target, as irradiation of mice lead to 
p53-dependent upregulation of NOXA40. NOXA belongs to the ‘BH3-only’ class of pro-
apoptotic proteins. The ectopic expression of NOXA triggers cell death while NOXA 
depletion protects from diverse apoptotic stimuli41. 
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NOXA acts as a “derepressor” protein by binding and specifically inhibiting MCL1 and 
A1 activity. The interaction between NOXA and MCL1 serves to displace BAK from 
MCL1, leading to cell death. In addition,  the binding of NOXA and MCL1 serves to target 
MCL1 for proteasomal degradation42. Treatment of multiple myeloma cell lines with the 
proteasomal inhibitor, Bortezomib, caused concomitant upregulation of NOXA and MCL1, 
leading to the cleavage of MCL1 through the activation of caspases43,44. Thus the 
NOXA/MCL1 axis appears to be critical in mediating cell death in response to diverse 
stimuli. It is still unclear whether functional inhibition of MCL1 by NOXA absolutely 
requires NOXA-mediated MCL1 degradation. 
The transcriptional regulation of NOXA expression itself is poorly understood, and both 
p53-dependent and -independent mechanisms have been described. As mentioned above, 
radiation-induced NOXA expression is p53-dependent. However, generation of reactive 
oxygen species by cisplatinum in chronic lymphocytic leukemia led to specific 
upregulation of NOXA in a p53-independent manner45. Regulation of NOXA at the post-
translation level is also complex. For example, NOXA can be turned over by the 
proteasome in a ubiquitin-dependent and -independent manner43,46. Interestingly, the 
degradation of NOXA is blocked by MCL1, which interacts with the BH3 domain of 
NOXA and stabilizes it46. This further emphasizes the importance of the NOXA-MCL1 
interactions in regulating the levels of both proteins.  
 
(v) BCLXL 
Similarly to MCL1, BCLXL is a key survival factor in numerous solid tumors. In 
particular, there is a high frequency of BCLXL amplification in colorectal cancers, and 
many of these tumors depend on this protein for survival47. BCLXL exerts its anti-
apoptotic activity by binding to and inhibiting the activity of the effector proteins BAX and 
BAK as well as the BH3-only proteins BIM and PUMA18. BCLXL activity can be 
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regulated through  phosphorylation by the JNK kinase48. This causes the release of BAX 
from BCLXL, leading to apoptosis. Targeting of BCLXL offers an attractive therapeutic 
strategy, and a number of specific inhibitors (e.g. WEHI-539) have been designed to 
specifically target this protein49.  
 
BH3 mimetics 
Many cancer cells depend on the up-regulation of the anti-apoptotic arm of the BCL-2 
pathway in order to evade cell death, thus acquiring unlimited proliferative capacity. 
The dependency on BCL2, BCLXL, and MCL1 serves to inhibit cell death through the 
formation of heterodimers between the anti-apoptotic proteins and pro-death members. 
This heterodimer formation is mediated via binding of the BH3 domain of pro-apoptotic 
proteins with the hydrophobic clefts found in anti-apoptotic proteins18. 
The hydrophobic cleft has become an attractive target for molecules designed to disrupt 
binding between anti- and pro-apoptotic proteins. The canonical compounds of this class 
are the BH3 mimetics, which act as competitive inhibitors by binding to the hydrophobic 
cleft. This in turn allows for the activation of pro-apoptotic members of the family50.  
In addition to their therapeutic potential, BH3 mimetics facilitate the functional dissection 
of the BCL-2 pathway. Chemical and genetic studies using BH3 mimetics have also 
elucidated key regulators of apoptosis. For example, an RNAi screen has uncovered a role 
for the RNA/DNA helicase DHX9 in sensitizing Eμ-Myc/Bcl-2 lymphomas to the BH3 
mimetic, ABT-73751. 
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Figure 1.6. BH3 mimetics mechanism of action 
BH3 mimetics are designed to “mimic” the BH3 domains of derepressor proteins 
such as BAD. By competitively binding to anti-apoptotic proteins, the activator 
proteins are released and can in turn activate the effector proteins BAX and BAK. 
 
ABT-737, a specific inhibitor of BCL2, BCLXL and BCLW, is the most well characterized 
of these compounds, and an orally available form (Navitoclax) is currently in phase I/II 
clinical trials52. Although this compound has shown great promise in the treatment of 
certain hematological malignancies, its BCLXL-inhibitory activity is associated with 
occurrence of thrombocytopenia53. This condition, which is characterized by the loss of 
platelets, results in ineffective clotting of blood and can lead to internal bleeding. In order 
to overcome this side effect, the first orally available BCL2 selective inhibitor, ABT-199 
has been developed. ABT-199 has shown promising anti-tumor activity in chronic 
lymphocytic leukemia (CLL), lymphomas and certain subsets of myelomas with reduced 
thrombocytopenia54.   
WEHI-539 was the first BCLXL specific inhibitor that was described to have on-target 
specificity in cell lines engineered to rely on BCLXL for survival49. However, WEHI-539 
has poor efficacy in vivo due to a potentially toxic hydrazone moiety and poor 
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physiochemical properties. This has led to the design of a more stable compound, A-
1155463, which has is a potent inducer of death in BCLXL-dependent colorectal cancer 
cell lines55. 
 
Figure 1.7.  BH3 mimetics 
Representation of BH3 mimetics that collectively target BCL2, BCLXL and 
BCLW, or exhibit selectivity for either BCL2 or BCLXL. (Images adapted from 
http://www.chemietek.com/) 
 
Although these compounds are the most potent BCL2/BCLXL inhibitors to date, they have 
little or no effect in MCL1-dependent leukemias and solid tumors. This is since none of 
them bind effectively to the MCL1 hydrophobic cleft56.  
One of the strategies to overcome this resistance has been to employ ABT-737 in 
combination with proteasome inhibitors such as Bortezomib. Bortezomib neutralizes 
MCL1 function through up-regulation of NOXA57. Alternatively, CDK1 inhibitors such as 
roscovitine inhibit the transcription of short-lived proteins such as MCL1 and have been 
used in combination with ABT-73758. A number of pan-BCL-2 inhibitors have also been 
developed in order to inhibit all the anti-apoptotic BCL-2 proteins. Amongst these, 
Obatoclax (GX-15-070) was found to inhibit the binding of anti-apoptotic family members 
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to pro-apoptotic BAX and BAK59. However, further studies have shown that this 
compound also initiates apoptosis in a BCL-2 independent manner, and that it possesses 
non-specific toxic effects. Thus, enthusiasm for obatoclax as a BCL-2 targeted therapy is 
somewhat tempered60. Two other potential MCL-1inhibitors, Maritoclax and Dinaciclib, 
are able to induce BAX/BAK and caspase activation. However, these effects were also 
observed in cells lacking MCL1, suggesting some off-target activities. These observations 
underscore the difficulty in designing specific MCL1 inhibitors61.  
A recent study has demonstrated that an indole-2-carboxylic acid core-based MCL1 
inhibitor, A1210477 shows increased binding affinity to MCL1 and is capable of 
specifically targeting MCL1 in various MCL1-dependent cell lines, including multiple 
myelomas and non small cell lung carcinoma lines. This leads to the disruption of 
MCL1:BIM complexes, thereby triggering activation of the intrinsic apoptotic pathway.  
A1210477 also synergizes with Navitoclax (ABT-263) to cause cell death in multiple 
cancer cell lines62. 
The efficacy of this MCL1-specific inhibitor in vivo and in clinical settings still remains to 
be seen. Thus, due to the lack of clinically relevant compounds specifically targeting 
MCL1, it is clear that further studies are required to fully elucidate MCL1 function and its 
regulation. This is turn would assist in specifically targeting this protein for therapeutic 
purposes. 
 
p53-dependent signaling 
One of the master regulators of apoptosis is the p53 tumor suppressor gene, which is 
activated in response to stress stimuli and induces apoptosis through both transcription-
dependent and -independent mechanisms63,64.  
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The death-inducing functions of p53 stem from its ability to regulate the transcription of 
the pro-apoptotic BCL-2 family members BAX, PUMA and NOXA6540,65.  This 
transcriptional up regulation is thought to affect the ratio of pro to anti-apoptotic proteins, 
thereby allowing for the release of cytochrome C, caspase activation and cell death63.  In 
addition, p53 can also regulate the transcription of CDKN1A (p21), an inhibitor of cell 
cycle progression, leading to cell cycle arrest rather than apoptosis66,67. The ultimate 
outcome of p53 activation is likely determined by the relative stoichiometry between its 
downstream apoptotic and cell cycle arrest proteins. As an example, genetic screens have 
identified transcription factors such as TCF3/E2A, which induces the expression of p21 
and represses PUMA. The depletion of TCF3 impairs cell cycle arrest and promotes 
PUMA-dependent apoptosis upon p53 activation. This demonstrates that the p21:PUMA 
ratio determines cell fate upon the activation of p5368. 
 Apart from its role as a nuclear transcription factor, p53 acts in the cytosol and at 
mitochondria to promote apoptosis through transcription-independent mechanisms69. This 
predominantly occurs through physical and functional interactions of p53 with the BCL-2 
family of proteins. Notably, p53 interacts with and activates the effector proteins BAK and 
BAX, thus directly activating apoptosis. In addition, the upregulation of PUMA upon p53 
activation also serves to activate BAX and BAK either directly, or through indirect means 
such as binding to BCLXL and BCL2. This allows for the release of sequestered pro-
apoptotic effectors. The interaction of p53 with pro-survival BCL-2 family members such 
as BCL2 and BCLXL has also been demonstrated in biochemical studies70,71,72,73.  
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Mitochondria: multitasking organelles 
The processes of mitochondrial fusion and division are important for maintenance of 
mitochondrial function and integrity. The balance between fusion and fission is essential 
for maintaining the mitochondrial network, for mitochondrial respiration, and for exchange 
of mitochondrial DNA. These two processes are therefore highly dynamic and serve to 
regulate mitochondrial morphology in response to different stimuli and cellular states, 
thereby dictating the mitochondrial signaling response74.  
 
(i) Regulation of fusion and fission 
Extensive studies in Drosophila melanogaster and yeast have identified key regulators of 
the mitochondrial fission and fusion machinery. The Drosophila gene Fzo and its yeast 
homologue, Fzo1, promote mitochondrial fusion. Screens performed in order to identify 
repressors of the fusion machinery led to the identification of molecules involved in 
mitochondrial fission. It has also been discovered that much of the fusion and fission 
machinery is conserved in mammalian systems75. 
In mammals, two large GTPases localized in the mitochondrial outer membrane, Mitofusin 
1 and 2 (MFN1, MFN2) form the key components of the outer membrane fusion 
machinery76,77. Mice lacking mitofusins display fragmented mitochondria and poor 
mitochondrial function and die during development78. Mutations in Mfn2 have also been 
linked to the onset of Charcot-Marie-Tooth disease, a neurodegenerative disorder 
characterized by muscle and nerve atrophy79. The fusion of the inner membrane is in turn 
regulated by the optic atrophy protein 1 (OPA1), which is a dynamin family GTPase 
localized to the mitochondrial inner membrane. Similar to the effects observed in the 
absence of mitofusins, the depletion of OPA1 also leads to mitochondrial fragmentation in 
addition to abnormal cristae structure75–77.  
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Mitochondrial fission in mammalian systems is mainly regulated by two proteins, 
dynamin-related protein 1 (DRP1) and FIS1. DRP1 is mainly localized in the cytosol but is 
recruited to fission sites on mitochondria. Inhibition of DRP1 leads to the formation of 
longer and interconnected mitochondrial networks. FIS1, the other key regulator of 
mitochondrial fission is distributed uniformly on the outer mitochondrial membrane and 
(like DRP1) its depletion results in elongated mitochondria80–83. 
 
 
Figure 1.8.  Mitochondrial Fusion and Fission 
Mitochondrial fusion is regulated by the outer membrane protein Mitofusin 2 
(MFN2) and the inner membrane protein Optic Atrophy protein 1 (OPA1). The 
mitochondrial fission or division process is mediated by the dynamin-related 
protein 1 (DRP1) and FIS1. 
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(ii) Fusion and fission in the control of cellular responses 
A tight regulation of mitochondrial dynamics is required in order to prevent alterations in 
organelle function and consequently changes in mitochondrial signaling pathways related 
to programmed cell death and metabolism. The proteins that regulate fusion and fission 
have therefore been implicated in the regulation of cellular responses such as 
bioenergetics, cell division, and apoptosis. 
Mitochondria undergo extensive fragmentation during apoptosis and this is predominantly 
regulated by the fission proteins, DRP1 and FIS1. The inner membrane fusion protein 
OPA1, which is required for maintaining cristae structure, can also prevent the release of 
cytochrome C80,82,84,85. In addition, the pro-apoptotic effector proteins BAX and BAK 
interact with members of the fusion and fission machinery in order to regulate 
mitochondrial morphology during the induction of apoptosis and are also required for the 
maintenance of normal mitochondrial networks22,86–88. Two anti-apoptotic BCL2 proteins, 
BCLXL and MCL1, can also localize to the inner membrane and mitochondrial matrix 
respectively, where they interact with and regulate components of the electron transport 
chain, thereby controlling ATP production89,38. 
The maintenance of an intact mitochondrial network is also crucial in regulating cell cycle 
progression. Over expression of MFN2 or inhibition of DRP1 with siRNA or a small 
molecule, mdivi-1, was sufficient to inhibit mitochondrial fission and induce cell cycle 
arrest and apoptosis21,80,85,90,91. Two major regulators of cell cycle progression, the cyclin 
B-CDK1 complex and Aurora A, can phosphorylate DRP1 enabling mitochondrial division 
during mitosis; this ensures the proper segregation of mitochondria into daughter cells92.  
The faithful division of mitochondria is essential for maintaining the integrity of the 
organelle during cell division. However, under conditions of stress such as that induced by 
the generation of excessive reactive oxygen species (ROS) or nutrient starvation, 
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mitochondria undergo hyperfusion. This prevents mitochondria from undergoing 
autophagosomal degradation and enhances energy production, thus enabling survival under 
non-optimal conditions.  This stress-induced mitochondria hyperfusion precedes the fission 
that occurs when cells undergo apoptosis, and is also dependent on the mitofusins and 
OPA1. The rearrangement of the mitochondrial network thus represents a pro-survival 
mechanism in response to stress conditions75,80,93–95. 
 
Ubiquitin pathway 
The ubiquitin system is responsible for post-translational modification of substrates in 
order to regulate their stability and function. Ubiquitin (Ub) is a highly conserved 8.5 kDa 
protein that is attached covalently to predominantly lysine residues of target proteins in a 
reversible manner. Target substrates can be modified by different types of Ub attachment: 
(i) attachment of a single ubiquitin molecule (monoubiquitination), (ii) single ubiquitin 
molecules at different sites on the protein (multiple monoubiquitination), or by ubiquitin 
chains (polyubiquitination).  
The ubiquitinated proteins can in turn be deubiquitinated by specific enzymes called 
deubiquitinases (DUBS)96,97.   
The actual conjugation of ubiquitin onto the target protein occurs in a three-step process 
that involves three discrete enzyme classes. These are E1 activating enzyme, E2 
conjugating enzyme, and an E3 ligase.  
The ubiquitin reaction is initiated by the activation of the ubiquitin molecule in an ATP-
dependent manner by the E1 activating enzyme and involves the formation of a thioester 
bond between the C-terminal carboxyl group of ubiquitin and an active Cys group of the 
E1 enzyme. The activated ubiquitin is then transferred from the Cys residue onto an E2 
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conjugating enzyme, again via formation of a thioester bond. The E3 ligases in turn 
recognize target substrates and recruit the E2 enzymes loaded with ubiquitin. The two 
major E3 ligase classes differ in regard to whether ubiquitin is directly conjugated to them 
(HECT E3 ligases) or not (RING E3 ligases) prior to its transfer to the substrate96,98–100. 
 
Figure 1.9. Ubiquitin Pathway 
The E1 activating enzyme binds to ubiquitin in an ATP-dependent process.  The 
ubiquitin conjugating enzyme E2 accepts ubiquitin from the E1 and transfers it to a 
protein substrate that is bound to the E3 ubiquitin ligase. The ubiquitin chain can 
then be extended. The ubiquitinated protein is then targeted to the 26 S proteasome 
in order to be degraded. This is a reversible process, since ubiquitin can be removed 
by a deubiquitinating enzyme.  
 
The formation of different ubiquitin chains dictates the fate of the targeted protein and in 
turn, of downstream signaling responses. Lysine 48-linked chains generally target the 
modified substrate to the proteasome for degradation. A specific example is that of the 
MDM2 E3 ligase, which targets the tumor suppressor p53 for degradation101. On the other 
hand, lysine 63-conjugated ubiquitin chains mediate signaling events, such as that 
observed following ubiquitination of the NF-κB pathway components NEMO by the 
TRAF6 ubiquitin ligase. This leads to activation of downstream signaling cascades 
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including those that lead to the activation of IKK and JNK kinases102. Monoubiquitination 
can regulate protein-protein interactions, and also regulates processes such as endocytosis. 
An example of the latter is monoubiquitination of the EGFR receptor, which is required for 
the receptor to be internalized103,104.  Other atypical ubiquitin chain types, such as those 
conjugated through lysine 27, are involved in processes such as PINK1/PARKIN-
dependent mitophagy. PARKIN mediates the formation of lysine 27-conjugated ubiquitin 
chains on mitochondrial proteins such as MIRO105. In addition, the cullin 3 ubiquitin ligase 
can catalyze K33-linked ubiquitination of CRN7 in order to regulate protein trafficking106.  
Recent studies have also identified a novel linkage mediated by methionine 1 of ubiquitin 
to form linear chains that are responsible for NF-κB activation107,108. 
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Figure 1.10.  Types of ubiquitin linkages  
 The ubiquitin molecule can be attached to the substrate in different manners. This 
in turn can target proteins for degradation or activate downstream signaling 
pathways. 
 
(i) E3 ubiquitin ligases 
The specificity of the ubiquitination reaction is dictated by the E3 ligases, which recognize 
the substrate and mediate the transfer of ubiquitin onto these proteins. The E3 ligases 
themselves are themselves regulated by phosphorylation and/or ubiquitination. In addition, 
acetylation of lysine residues also dictates protein stability by preventing proteasome- 
mediated degradation of proteins. Different families of E3 ligases regulate the final steps of 
the ubiquitination cascade109. 
(a) HECT family of E3 ligases 
The homologous to E6-AP carboxyl terminus (HECT) E3 ligases are characterized by the 
presence of a C-terminal HECT domain, which was first identified in the E6-associated 
protein. This protein was originally identified as an ancillary factor required for 
degradation of p53 by the human papillomavirus E6 oncoprotein. The HECT domain 
ligases possess intrinsic catalytic activity and mediate ubiquitination by binding to an 
ubiquitin-charged E2. This is followed by direct conjugation of ubiquitin onto the E3 ligase 
itself through the formation of a thioester bond with a catalytic Cys residue located in the 
C-terminus of the HECT domain. The ubiquitin molecule is then transferred directly onto 
the target protein. This category of E3 ligases includes the NEDD4 family members. This 
family of ligases mediate the ubiquitination and degradation of membrane proteins such as 
ion channels and receptors via endocytosis100,110. 
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(b) RING finger E3 ligases 
Most E3 ubiquitin ligases belong to the family of Really Interesting New Gene (RING) 
domain containing family of E3 ligases. In contrast to HECT ligases, RING E3s catalyze 
the transfer of ubiquitin directly from the E2 conjugating enzyme onto the substrate 
without forming an E2-E3 intermediate. Over 600 RING domain ligases have been 
identified in mammals.  The RING domains can coordinate two Zn2 + ions in a cross-
braced arrangement which creates a platform for binding of E2 enzymes. The RING 
domains can adopt different conformations, which are summarized in the table below99,111. 
RING Type Sequence Example 
RING-HC C2H2C4 MDM2 
RING-HC C3HC4 
c-CBL, 
BRCA1/BARD1, 
cIAP-1, -2, PML 
RING-CH C4HC3 
MARCH5 
MULAN 
RING-H2 C3H2C3 PIRH1, RBX2 
 
Figure 1.11. Tabulated summary of RING domain conformations 
Different E3 ligases possessing different conformations within their RING domain. 
MARCH5 possesses the C4HC3 conformation i.e. four cysteine residues, a 
histidine and three cysteines within the eight Zn2+ coordinating residues. 
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Some RING E3 ligases can dimerize through their RING domains to form homodimers 
(e.g., cIAP and TRAF2)112 or heterodimers (MDM2/MDMX and BRCA1/BARD1). This 
dimerization is thought to be required for functional regulation of E3 ligase activity. For 
example the formation of a heterodimer between MDM2 and MDMX allows for the 
stabilization of MDM2, thereby leading to more effective degradation of its target 
substrate, p53113. 
RING domain ligases can also exist in multisubunit complexes. Examples are the Cullin-
RING E3 ubiquitin ligases (CRLs), which are the most abundant class of E3 ligases. They 
are multi-subunit complexes composed of RING proteins coupled to cullins. The cullins 
act as scaffold proteins for their cognate E3 ubiquitin ligase. This complex also consists of 
diverse adaptor proteins that recruit substrates for ubiquitination. Examples of CRLs 
include the Skp, Cullin, F-box containing complex or SCF complex, which regulates cell 
cycle progression99,111,114. 
The dysfunction or abnormal expression of these E3 ligases can contribute to various 
disease states, including cancer. Several RING E3 ligases have been described as tumor 
suppressors or as oncoproteins. These include IAP family members, which inhibit caspase-
dependent cell death, and the SCF E3 ligases whose dysregulation leads to uncontrolled 
proliferation and genomic instability.  In the case of IAPs, their molecular interactions are 
well characterized, which had greatly facilitated their validation as therapeutic targets. 
Several Smac mimetic agents, that inhibit IAPs are being tested in clinical trials e.g. 
birinapanet 12. It is likely many other ligases will be added to the list of therapeutic targets 
once the molecular mechanisms associated with their biological activity are more 
thoroughly delineated33,100,101,115,116. 
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Figure 1.12.  HECT and RING domain E3 ligases 
HECT and RING domain E3 ligases differ in the transfer of ubiquitin onto target 
substrates. HECT ligases form a E3 ubiquitin intermediate while the RING E3 
ligases mediate direct transfer of ubiquitin onto substrates. 
 
(ii) Deubiquitinases (DUBs) 
The removal of ubiquitin from proteins is an equally important process that regulates 
protein stability and function. Around 100 DUBs have been identified in mammals, and 
they can be divided into five families based on their catalytic domains. These include the 
USP, OTU, UCH, Josephin, or JAMM/MPN+ domains117.  DUBs have important roles in 
diverse cellular processes such as the cell cycle (CYLD and USP13)118, chromatin 
remodeling (USP21 and USP22)119 and regulation of signaling pathways (A20 modulates 
the NF-κB pathway and USP7 regulates the MDM2-p53 pathway)120,121. Given that DUBs 
regulate key growth and survival pathways, it is not surprising that some have oncogenic 
(e.g. USP28) or tumor suppressor (e.g. CYLD) properties. 
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Mitochondria-dependent ubiquitin signaling 
Ubiquitination is a critical regulator of mitochondrial signaling pathways and 
mitochondrial quality control. Several E3 ligases are either localized to mitochondrial 
membranes, or are recruited to mitochondria in response to specific stimuli. These include 
mitochondrial ligases such MULAN, which regulates NF-κB signaling at the mitochondria 
and PARKIN, an E3 ligase that is recruited to mitochondria upon the induction of 
mitophagy122. 
 
(i) Mitochondrial apoptotic signaling 
The mitochondrial or intrinsic apoptotic pathway is regulated by a group of RING E3 
ligases called inhibitors of apoptosis proteins (IAPs). These proteins inhibit apoptosis by 
preventing the activation of caspases. The X-chromosome-linked IAP (XIAP) and cellular 
IAP1 (c-IAP1) bind to caspases 3, 7 and 9, block their catalytic activity and regulate their 
levels through ubiquitin-dependent targeting for proteasomal degradation123. 
RNF144B, an E3 ligase with an ‘in between RING’ (IBR) domain is recruited to 
mitochondria where it interacts with activated BAX and regulates its ubiquitination and 
stability124.  
In addition, the levels and functions of other BCL-2 family members are also regulated 
through ubiquitination. For example the unphosphorylated form of BCL2 is targeted for 
ubiquitination and subsequent degradation125. The E3 ligases in this process however, have 
not been identified. In addition, the MCL1 protein is ubiquitinated by MULE and other E3 
ligases and this depends on MCL1 phosphorylation status32,34. However, most of these 
ubiquitin ligases are localized to the cytosol and are recruited to mitochondria in a 
stimulus-specific manner. Whether additional E3 ligases located in the mitochondrial outer 
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membrane can directly regulate the BCL2 family of proteins to co-ordinate the apoptotic 
response remains unclear.  
 
(ii) Innate immune signaling  
Another mitochondrial signaling pathway that is ubiquitin-dependent is the NF-κB 
pathway. The mitochondrial associated viral sensor (MAVS), is located on the 
mitochondrial outer membrane, and acts as an adaptor for E3 ligases such as TRAF3 and 
TRAF6. These ligases bind and mediate ubiquitination of the NF-κB essential modifier 
(NEMO), which in turn activates downstream IKK and promotes transcription of target 
genes. The mitochondrial RING domain E3 ligase MULAN also regulates NF-κB 
activation through the ubiquitination of TRAF2 under stress conditions. This in turn leads 
to increased transcription of pro-inflammatory cytokines and anti-apoptotic proteins, 
thereby enabling cell survival102,122,126,127. 
 
(iii) Mitochondrial quality control 
It is essential that quality control systems are present to maintain optimal mitochondrial 
function. The most well studied quality control system is mitophagy, which is regulated by 
PINK1 (PTEN-induced kinase 1) and PARKIN128,129. 
 The IBR E3 ligase, PARKIN, co-operates with PINK1 to remove damaged or 
dysfunctional mitochondria. The activation and stabilization of PINK1 leads to recruitment 
of PARKIN from the cytosol to the mitochondria, where it is responsible for ubiquitinating 
many outer mitochondrial membrane proteins. The ubiquitination of substrates, which 
include TOMM20, MFN1/2, and VDAC1, serves as a signal to recruit autophagosomes to 
the mitochondria. Mutations in PINK1 or PARKIN prevent autophagosome formation, and 
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thus engender the accumulation of damaged mitochondria130,131. This has direct clinical 
relevance, since mutations in both PINK1 and PARKIN are associated with mitochondrial 
dysfunction that accompanies the symptoms of Parkinsons’ disease132. Intriguingly, 
PINK1/PARKIN mutations have also been found in cancer tissue, suggesting aberrations 
in these proteins may also contribute to the transformed phenotype133. Whether this is due 
to increased mitochondrial dysfunction, or because of improper regulation of other targets 
of PINK1/PARKIN remains unclear. Further studies of PINK1/PARKIN and their 
functional interactions with other mitochondrial outer membrane and cytosolic proteins are 
clearly warranted in this regard. 
 
MARCH5 Ubiquitin Ligase 
MARCH5 is a RING domain E3 ligase that is localized to the mitochondrial outer 
membrane. The protein contains an N-terminal RING domain and four transmembrane 
domains134.  
 
 
 
Figure 1.13. MARCH5 ubiquitin ligase 
MARCH5 possesses an amino terminus RING domain and four mitochondrial 
membrane spanning domains. The RING domain possesses the critical catalytic 
residues important for transfer of ubiquitin onto the target substrate.  
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MARCH5 belongs to the group of Membrane-associated RING-CH (MARCH) proteins. 
RING-CH proteins have a cysteine residue in the fourth position and a histidine in the fifth 
position of the RING domain. This conformation is also characteristic of membrane 
associated E3 ligases. The MARCH family of proteins were originally described as 
homologs of K3 and K5, which are E3 encoded by Kaposi’s sarcoma-associated 
herpesvirus (KSHV). There are eleven members in this family, each of which possesses a 
RING-CH domain, at least one transmembrane domain, and E3 ubiquitin ligase activity. 
The specific functions of each MARCH5 member are tabulated below135. 
 
MARCH Family 
Member 
Function Subcellular Localization 
MARCH1 Ubiquitination of MHC II and 
antigen presentation 
Plasma membrane, 
endosomes 
   
MARCH2 Endosomal trafficking Plasma membrane, 
endosomes 
   
MARCH3 Endosomal trafficking Endosomes 
   
MARCH4 Regulation of MHC I Golgi apparatus 
   
MARCH5 Mitochondrial dynamics, innate 
immune signaling 
Mitochondria 
MARCH6 ER protein degradation Endoplasmic reticulum 
   
MARCH7 Regulation of lymphocytes, general 
proliferation 
Nucleus, cytosol and 
plasma membrane 
   
MARCH8 Downregulation of MHC I, 
transferrin receptor and 
ubiquitination of MHC II 
Endosomes 
   
MARCH9 Ubiquitination of MHC I and ICAM Lysosomes 
   
MARCH10 Unknown Spermatids-association 
with microtubules 
   
MARCH11 Ubiquitin dependent endosomal 
protein sorting 
Multi-vesicular bodies 
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Figure 1.14. Table summarizing the functions of MARCH family members 
MARCH family members are localized to diverse cellular compartments and 
mainly involved in protein turnover.  
 
MARCH5 is the only family member localized to the mitochondria, and is therefore 
perfectly situated to regulate neighboring mitochondrial proteins and/or signaling events 
that occur on the mitochondrial outer membrane136.  
MARCH5 plays a role in mitochondrial dynamics by interacting with proteins that control 
fusion and fission, thereby regulating mitochondrial morphology and function.  Mitofusin 
2 (MFN2) has been identified as a MARCH5 substrate, and this interaction is important in 
mediating mitochondrial fusion as well as mitochondrial-endoplasmic reticulum 
interactions. This interaction is critical for the maintenance of calcium homeostasis137. 
Another fusion protein, mitofusin 1 (MFN1) is also ubiquitinated by MARCH5, and this 
interaction increases in response to mitochondrial stress. The MARCH5-dependent 
ubiquitination of acetylated MFN1 serves to modulate levels of MFN1 protein under stress 
conditions138.  
MARCH5 depletion leads to hyperfusion of mitochondria, which is followed by an 
increase in intracellular ROS and induction of cellular senescence139. In addition, 
MARCH5 can also regulate the levels of misfolded proteins within the mitochondria, 
thereby exhibiting a quality control function. Specifically, MARCH5 can ubiquitinate 
manganese superoxide dismutase and S-nitrosylated LC1, leading to their degradation140–
142. This has clinical implications, as loss of function of these proteins leads to 
mitochondrial stress associated with Parkinson’s disease.  
33 
 
In addition, MARCH5 also has a role in the innate immune response as it ubiquitinates and 
TANK, a negative regulator of TRAF6, following initiation of Toll-like Receptor 7 (TLR7) 
signaling. This enhances TLR7 signaling, as the resulting derepression of TRAF6 in turn 
activates the NF-κB pathway143.  An opposing role for MARCH5 in innate immune 
signaling has been demonstrated by recent reports that show a negative regulation of the 
mitochondrial anti-viral signaling (MAVS) by MARCH5 thereby preventing excessive 
host immune response144. Thus, the role of MARCH5 in this context remains unclear and 
may be dependent on the type of upstream immunogenic stimulus. 
Strikingly MARCH5 is also implicated in the maintenance of pluripotency in embryonic 
stem cells. Mechanistically, this is via catalyzing K63-linked polyubiquitination of 
PRKAR1a, a negative regulatory subunit of PKA. The subsequent activation of PKA leads 
to inhibition of RAF/MEK/ERK signaling; inhibition of ERK signaling is required for 
maintenance of pluripotency145.  
Anecdotal reports suggest that MARCH5 knockout mice display degenerative phenotypes 
similar to those found in murine Alzheimer models (unpublished data), indicating that 
prolonged depletion of MARCH5 is deleterious, at least in a neurological context146.  
Studies on the role of MARCH5 in the regulation of MAVS also described the 
homozygous deletion of MARCH5 as being embryonic lethal144. Taken together, these 
studies suggest MARCH5 plays a protective role in cells. 
However, the role of MARCH5 in the regulation of other mitochondrial signaling 
pathways is virtually unexplored. Given that MARCH5 appears to be critical for the 
maintenance of mitochondrial homeostasis, we hypothesized that it might directly or 
indirectly regulate cell death signaling, as many events in both the intrinsic and extrinsic 
apoptotic pathways converge at the mitochondria. 
34 
 
Through chemical and genetic approaches introduced in the following chapters, we 
demonstrate that MARCH5 has a direct functional interaction with the intrinsic apoptotic 
pathway. This is due to MARCH5-dependent regulation of the MCL1/NOXA axis, which 
dictates the threshold for sensitivity to specific BH3 mimetics. The significance of this in a 
biological context, as well as from a clinical perspective, will be discussed. 
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CHAPTER 2. MATERIALS AND METHODS 
 
Cell culture 
Cells were grown in McCoy’s 5A (HCT116), DMEM (U2OS, MDA-MB-231, and HeLa), 
or DMEM/HAM’s F12 (MDA-MB-468) media supplemented with 10% fetal bovine 
serum, 4 mM L-glutamine, 100 U/ml penicillin, and 100 U/ml of streptomycin, in a 
humidified atmosphere of 5% CO2 at 37°C. Cells were passaged prior to reaching full 
confluency for general maintenance. DMEM, L-glutamine, penicillin and 
streptomycin were purchased from Lonza (Basel, Switzerland). McCoy’s 5A and 
HAM’s F12 were purchased from Gibco (ThermoFisher Scientific, MA, USA). Cells 
were purchased from ATCC (Manassas, VA). HCT116 p53-/-, BAX-/-, BAK-/- and 
BAX/BAK-/- were a kind gift from Dr. Bert Vogelstein, Johns Hopkins University. HeLa 
NOXAWT and NOXAL29E  inducible cell lines were a kind gift from Dr. Andreas Villunger, 
Biocenter - Innsbruck Medical University. 
 
Compound treatments 
For compound treatments, cells were allowed to attach overnight and then treated 
with the indicated concentrations of compounds. All the solutions were adjusted to have 
an equivalent amount of DMSO (final DMSO not more than 0.1% in all experiments). 
Nutlin-3a was purchased from Sigma-Aldrich (St. Louis, MO, USA), ABT-737 was 
from Santa Cruz (Dallas, TX, USA), ABT-199 from Selleckchem (Houston, Texas, 
USA), and WEHI-539 (BCLXL inhibitor) and A1210477 (MCL1 inhibitor) were 
purchased from Chemietek (Indianapolis, IN, USA). MG-132 was purchased from 
Enzo Life Sciences (Farmingdale, NY, USA) and doxycycline, cycloheximide, CCCP, 
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and mdivi-1 from Sigma Aldrich (St. Louis, MO, USA). For cycloheximide pulse chase 
assays, cells were then treated with cycloheximide (100 μg/ml) for the given time points 
before being subjected to western blot analysis. 
 
Colony formation assay and quantification 
U2OS osteosarcoma cell lines transfected with either siRLUC or siMARCH5 were plated 
at a density of 100 cells/well on black clear-bottom optical 96-well plates. Cells were 
treated the following day with ABT-737 at the indicated doses. Colony formation was 
monitored for 6–7 days.  The colonies were then fixed and stained with DAPI and HCS 
CellMask Red Stain (Life Technologies). The 96-well assay plates were scanned using a 
Nikon Ti-Eclipse widefield microscope (Ti-Eclipse; Nikon) with a 4× objective in order to 
acquire a large area of the well. Image processing and analysis pipelines are further 
described in Ricci et al., 2015147. 
 
Plasmids, expression constructs and mutagenesis 
Wild type human MARCH5 with a 3× N-terminal FLAG tag (a kind gift of Professor 
Shigehisa Hirose, Tokyo Institute of Technology) was subcloned into pLi196, a Dox-
responsive entry vector for RMCE148. Using this plasmid as a template, the MARCH5 
mutants were generated by site-directed mutagenesis (Stratagene). The primers used for the 
mutagenesis were as follows: 
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Mutants Forward (5'-3') Reverse (5'-3') 
H43W tgtagacaggcctgccaaacccattttgtagatcctct ggtgcagaggatctacaaaatgggtttggcaggcctgt 
  Gcacc ctaca 
  
 
  
C65SC68S attcagcattgctctgaggacttgccactctggctgtac attcagcattgctctgaggacttgccactctggctgtac 
      
V16A catcagtagcaaaacaagcccagcaacttctgtcc ggacagaagttgctgggcttgttttgctactgatg 
      
V51A ctctttgcttttcatccgcccagcgttgtagacag ctgtctacaacgctgggcggatgaaaagcaaagag 
      
P66A cagcattgcactgagcacatgccactctggc gccagagtggcatgtgctcagtgcaatgctg 
      
D202Y gagtagcagagacatgatatgctaaaggattggcctc gaggccaatcctttagcatatcatgtctctgctactc 
      
D202G gagtagcagagacatgacctgctaaaggattggcc ggccaatcctttagcaggtcatgtctctgctactc 
 
 
For transfection, U2OS cells were plated on 100-mm plates and transfected with 5 μg of 
empty vector or HA-ubiquitin (a kind gift from Dr. Simona Polo) with Lipofectamine 3000 
reagent (Life Technologies). Media was changed 6 h post-transfection and cells were 
harvested after 48 h. 
 
Generation of cell lines 
All Dox-inducible FLAG-MARCH5 cell lines were created by recombination mediated 
cassette exchange (RMCE) of Doxycyline-responsive FLAG-MARCH5 plasmids into 
a master parental U2OS cell line as previously described149. Cells were induced with Dox 
(50 ng/ml) for 24 h to induce expression of the various FLAG-MARCH5 constructs before 
harvesting for western blot analysis. For RNAi experiments, cells were transfected with 
siRNA for 24 h and then induced with Dox for a further 24 h. 
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RNAi experiments 
siGENOME SMARTpool siRNAs for MARCH5, Renilla luciferase negative control, 
PLK1 positive control, MCL1, BIM, NOXA, and RNF144B were purchased from GE 
Life Sciences/Dharmacon (Lafayette, CO, USA) and used at a final concentration of 25 
nM. Cells were seeded on 6-well plates for forward transfection. U2OS cells were 
transfected with 3 μl DharmaFECT 1 (Dharmacon); HCT116, MDA-MB-231, MDA-MB-
468 and HeLa cells were transfected with 3 μl RNAiMAX (Life Technologies). Cells were 
harvested 48 h post-transfection for protein and RNA extraction or seeded on 96-well 
plates 24 h post-transfection and treated with compounds the following day for viability 
assays. Deconvolution experiments were performed with siGENOME individual siRNAs 
as well as C911 controls. siRNA sequences are tabulated below.  
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Gene Symbol Gene ID Catalog Number Sequences 
MARCH5 54708 M-007001-01 UCAAACAGCAGCAAUAUUU 
      GGACAGCUGUGACUUAUGG 
      GUAAAUUGAUGUUCAGUAG 
      GACAGAAGUUGCUGGGUUU 
MARCH5 C911 
Controls n/a Custom 
GUAAAUUGAUGUUCAGUAG 
      GCUGAAUACCUAAUAGUUU 
      GCGCAAAUACUCGAAUAAA 
      GAAUAAUGGUCGGCUCUAU 
MCL1 4170 M-004501-008 CGAAGGAAGUAUCGAAUUU 
      AGAACGAAUUGAUGUGUAA 
      GGACCAACUACAAAUUAAU 
      GCUACGUAGUUCGGGCAAA 
BIM 10018 M-004383-02 CCGAGAAGGUAGACAAUUG 
      UGAUGUAAGUUCUGAGUGU 
      AUGUAAGUUCUGAGUGUGA 
      GUUCUGAGUGUGACCGAGA 
NOXA 5366 M-005725-03 AAACUGAACUUCCGGCAGA 
      AAUCUGAUAUCCAAACUCU 
      CUGGAAGUCGAGUGUGCUA 
      GCAAGAACGCUCAACCGAG 
PLK1 5347 M-003290-01 CAACCAAAGUCGAAUAUGA 
      CAAGAAGAAUGAAUACAGU 
      GAAGAUGUCCAUGGAAAUA 
      CAACACGCCUCAUCCUCUA 
RNF144B 255488 M-025119-01 CAGCUUGCCUGAAACAGUA 
      AAGCUGAGAUUGCCUGUUU 
      GUAGAGACAGUCAGCCUAU 
      GGGUUUAUAUCGAACGCAA 
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Western blots and antibodies 
Cells were lyzed in 0.5% NP-40 lysis buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 150 
mM NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 
10 mM NaF and Complete Mini Protease Inhibitors (Roche, Nutley, NJ, USA), at 
4 °C for 30 min. Following SDS-PAGE electrophoresis, proteins were transferred 
onto nitrocellulose membranes. Membranes were incubated with the following 
antibodies: anti-MARCH5 (a gift of Dr. Nobuhiro Nakamura, Tokyo Institute of 
Technology), anti-PARP (BD Biosciences), anti-MCL1 (Santa Cruz Biotechnologies), 
anti-PUMA (Santa Cruz Biotechnologies), anti-Actin (Sigma-Aldrich), anti-Vinculin 
(Sigma-Aldrich) anti-NOXA (Calbiochem), anti-p53 (Santa Cruz Biotechnologies), anti-
BCL2 (BD Biosciences), anti-BCL-XL (Cell Signaling Technologies), anti-cleaved 
caspase 3 (Cell Signaling Technologies) and anti-FLAG (Sigma-Aldrich). Rabbit and 
mouse secondary antibodies were purchased from Bio-Rad Laboratories. Blots were 
developed using Clarity Western ECL Substrate (Bio-Rad Laboratories). 
 
Immunoprecipitation 
Cells were lysed in IP lysis buffer consisting of 50 mM Tris, pH 8.0, 5 mM EDTA, 
150 mM NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 10 mM 
NaF, Complete Mini Protease Inhibitors (Roche, Nutley, NJ, USA) and 25 μM PR-619 
DUB inhibitor (Calbiochem), at 4°C for 30 min. Supernatants were then incubated for 4 h 
with HA Epitope Tag Antibody, Agarose conjugate (2-2.2.14) under constant rotation at 
4°C. Beads were washed five times in ice-cold lysis buffer and eluted protein was 
subjected to SDS-PAGE and immunoblotted with the indicated antibodies. 
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Viability assay 
Cell viability was assessed 24 h after drug treatment using the CellTiterGlo 
Luminescent Cell Viability Assay (Promega, Fitchburg, WI, USA) per the 
manufacturer’s instructions. Following compound treatments, CellTiterGlo reagent 
was added to the cells; after a 10-min incubation period to allow for stabilization of 
luminescence, samples were transferred to solid white multiwell plates and 
luminescence was read on a PHERAstar FS microplate reader (BMG LABTECH, 
Ortenberg, Germany). 
 
qRT-PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and complementary DNA 
(cDNA) was synthesized using the ImProm-II Reverse Transcription System 
(Promega). Ten nanograms cDNA was used per PCR reaction with SYBR Green 
PCR Master Mix (Applied Biosystems, ABI) and quantified on the BIORAD CFX96 
Real Time System. Fold changes in mRNA expression was quantified using the Δ-ΔCt 
algorithm with 18S ribosomal RNA as loading control. qPCR primers are tabulated below. 
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  Forward (5'-3') Reverse (5'-3') 
18S GATTAAGTCCCTGCCCTTTGTACA GATCCGAGGGCCTCACTAAAC 
      
MARCH5 GATGCTGGACAGAAGTTGCTGG CCACTCTGGCTGTACTGTTTCC 
      
MCL-1 GGTGCCTTTGTGGCCAAACACTTA ACCCATCCCAGCCTCTTTGTTTGA 
      
PUMA ACGACCTCAACGCACAGTACG TCCCATGATGAGATTGTACAGGAC 
      
p21 CTGGAGACTCTCAGGGTCGAAA GATTAGGGCTTCCTCTTGGAGAA 
      
NOXA CAGGACTGTTCGTGTTCAGC TTCTGCCGGAAGTTCAGTTT 
      
RNF144B CATTATGACAAAGGGCCATGC CATACATTTTGCTGGTACTGCC 
      
BIM TGGCAAAGCAACCTTCTGATG GCAGGCTGCAATTGTCTACCT 
      
 
 
Immunofluorescence 
U2OS were seeded onto coverslips pre-coated with gelatin. Following RNAi, 
compound treatments or transfections with FLAG-MARCH5 constructs, cells were fixed 
in 4% paraformaldehyde. Cells were permeabilized with 0.05% Triton X-100 and 
coverslips were blocked in 10% bovine serum albumin/PBS for 20 min. Cells were 
incubated with anti-TOMM20 (Santa Cruz Biotechnology) at 1:100 dilution for 1 h to stain 
mitochondria and/or anti-FLAG M2 (Sigma-Aldrich) at a dilution of 1:1000. Following 
three washes with PBS, cells were incubated with Alexa-488 (Life Technologies) at a 
dilution of 1:400, Alexa-647 at a dilution of 1:400 and DAPI (1:3000) for 1 h. Coverslips 
were washed and mounted with glycerol on glass slides. Imaging was performed on the 
Leica TCS SP2 AOBS laser confocal scanner mounted on a Leica DM-IRE2 inverted 
microscope with a 63× oil immersion objective. 
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Quantification of perinuclear mitochondria 
For the quantification of perinuclear mitochondria, U2OS cells were transfected on 96 
multi-well black optical clear plates for 72 h, fixed and stained for TOMM20 and DAPI. 
Images were acquired by a 20× objective on  a  Nikon Ti-Eclipse widefield microscope 
(Ti-Eclipse; Nikon).  Segmentation of nuclei was performed and the cytoplasm was 
defined based on the nuclear region. A region of interest (ROI) was applied around the 
nucleus and mitochondria staining was quantified in this ring region. Analysis and 
quantification was performed on the Columbus Image Data Storage and Analysis System 
(PerkinElmer). 
 
Measurement of mitochondrial membrane potential 
U2OS cells transfected with siRLUC or siMARCH5 on 96 multi-well black optical clear 
plates for 72 h were stained with TMRE. TMRE is a cell permeable, positively-charged, 
red-orange dye that readily accumulates in active mitochondria due to their relative 
negative charge. Depolarized or inactive mitochondria have decreased membrane potential 
and fail to sequester TMRE. Nuclei were stained with Hoechst and live cell imaging was 
performed with a 20× objective on a Nikon Ti-Eclipse widefield microscope (Ti-Eclipse; 
Nikon). Nuclear and cytoplasmic regions were defined during image segmentation and the 
intensity of the TMRE signal within the cytoplasmic compartment was quantified. 
Analysis and quantification was performed on the Columbus Image Data Storage and 
Analysis System (PerkinElmer). 
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Gene expression and multivariate analysis 
We used a classical statistical modeling approach (Multiple Linear Regression with 
multiple variables150) to relate drug sensitivity to the expression profiles of 8 selected 
genes. Data for sensitivity to ABT-263 were downloaded from the Wellcome 
‘Genomics of Drug Sensitivity in Cancer’ database 
(http://www.cancerrxgene.org/translation/Drug/1011) and RNA expression data for 
the corresponding cell lines were retrieved from the ‘Whole Genome Project’ section 
of the COSMIC public database (http://cancer.sanger.ac.uk/cosmic) of the Welcome 
Trust Sanger Institute.   
 
For 648 of the 971 cell lines in the database, both ABT sensitivity and mRNA expression 
data (for MARCH5, MCL1, BIM, BAX, HUWE1, BAK1, NOXA, and BCLXL) were 
available. The RNA expression levels are all normalized (z-score) in order to standardize 
gene expression estimates obtained different platforms used for sequencing the samples 
(IlluminaHiSeq_RNASeqV2, IlluminaGA_RNASeqV2, AgilentG4502A_07_3). For the 
sensitivity parameter in our models, we used IC50 values for ABT-263 for each cell line.  
 
For some analyses, we further subdivided thedataset into cell lines with wild type p53 (221 
samples) and those with mutant/deleted p53 (427 samples). For optimization of the model, 
we used the Akaike Information Criterion (AIC). The model optimization was done in a 
backward selection fashion, starting from the full linear model specification, (i.e., mRNA 
expression levels for each individual gene, and for all possible pairwise combinations were 
provided prior to optimization). Optimization was run separately for each individual subset 
(all wild type p53 samples, all mutant samples, or blood wild type p53 samples).  
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Statistical analysis 
Statistical analysis was performed using an unpaired Student’s t-test. Data were calculated 
as mean and standard deviation. Statistical significance is represented in figures by 
asterisks as follows: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001. 
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CHAPTER 3. RESULTS 
 
(I) INTERACTION OF MARCH5 WITH THE BCL-2 PATHWAY 
 
MARCH5 depletion sensitizes to BH3 mimetic induced apoptosis 
Given that MARCH5 is localized to the mitochondrial outer membrane and appears to 
promote cell survival, we hypothesized that MARCH5 might have functional interactions 
with the mitochondrial apoptotic pathway. In order to investigate this, clonogenic analysis 
was performed by transfecting the U2OS osteosarcoma cell line with siRNA targeting 
MARCH5 or siRLUC control, seeding cells at low density and assessing the colony 
forming potential upon treatment with the BH3 mimetic, ABT-737. ABT-737 is an 
efficient tool to dissect the mitochondrial apoptotic pathway as it is a specific inhibitor of 
BCL2, BCLXL, and BCLW52.   
 The depletion of MARCH5 in combination with the drug led to the formation of smaller 
and fewer colonies quantified as percentage area covered by colonies (Fig. 3.1a). This 
experiment was also repeated at high cell density in U2OS and HCT116 (human colorectal 
carcinoma cells). The depletion of MARCH5 sensitized cells to ABT-737, while little or 
no effects were observed with administration of the drug alone (Fig. 3.1b). The mode of 
cell death was confirmed as mitochondrial apoptosis, indicated by the cleavage of the 
caspase 3 and its downstream substrate, PARP (Fig. 3.1c).  
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Figure 3.1. MARCH5 depletion sensitizes solid tumor cell lines to BH3-mimetic 
induced apoptosis 
(a) U2OS osteosarcoma cell lines were transfected with siRNA targeting MARCH5 or 
a control siRNA. Cells were then plated on 96-well plates at low density and 
treated with ABT-737 (Black bar: DMSO, red: 0.5 µM, dark grey: 1 µM, light 
grey: 5 µM, white: 10 µM) and colony formation was monitored for 7 d.  After 7 d, 
cells were fixed and stained with DAPI and HCS CellMask red stain and 
percentage area covered by colonies was then calculated. 
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(b) U2OS and HCT116 colorectal cancer cell lines transfected with siRNA targeting 
MARCH5 as well as a control siRNA targeting luciferase (RLUC) were treated 
with ABT-737 (Black bar: DMSO, red: 5 µM,  grey: 10 µM). The cell viability was 
measured using CellTiter-Glo. The error bars represent the SD from triplicate 
experiments. The asterisks (***) indicate a p value of < 0.001 compared to the 
respective controls using Student’s t-test. 
(c) Whole cell lysates from U2OS and HCT116 cells transfected with siRLUC or 
siMARCH5 and treated with ABT-737 (10 μM) were subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. The extent of PARP cleavage was 
quantified as the ratio of cleaved to full length PARP. 
 
In order to validate that this sensitization was on-target, several independent siRNAs 
targeting MARCH5 were used. In addition, C911 control siRNAs were also included in the 
validation experiment. These siRNAs possess the same “seed” region as the biologically 
active siRNA but have bases 9-11 scrambled.  These sequences therefore provide 
information about potential seed-based off-target effects. The sensitization to ABT-737 
was phenocopied by the additional siRNAs (Fig. 3.2a) while three of four C911 controls 
failed to knockdown MARCH5 mRNA (Fig.3.2b) and “rescued” this phenotype (Fig. 
3.3a). C911 control-1 did not rescue this phenotype. This could be attributed to some 
residual ability to knock down MARCH5 mRNA (Fig. 3.2b). In addition, the knockdown of 
another mitochondrial ubiquitin ligase, RNF144B, did not sensitize cells to ABT-737, 
indicating that this effect was specific to MARCH5 (Fig. 3.2b). 
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Figure 3.2. Sensitization to ABT-737 upon MARCH5 loss is on-target  
(a) HCT116 cells were transfected with the given siRNAs and treated with ABT-
737 (Black bar: DMSO, red: 5 µM, grey: 10 µM). Cell viability was measured 
using CellTiter-Glo. The error bars represent the SD from triplicate 
measurements for each condition. 
(b) Knockdown of MARCH5 and RNF144B mRNA was validated by quantitative 
RT-PCR. Values were normalized to 18S mRNA used as loading control. 
 
Sensitization to apoptosis upon MARCH5 depletion is dependent on the 
BH3 effector protein, BAX 
The two terminal effector proteins involved in the release of cytochrome C from 
mitochondria upon membrane permeabilization are BAX and BAK. The requirement for 
each of these proteins for induction of cell death depends on the precise apoptotic stimulus 
and cellular context11. The use of single or double knockout isogenic cell lines for these 
proteins revealed that MARCH5-dependent sensitization was BAX-dependent but BAK-
independent (Fig. 3.3). 
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Figure 3.3. MARCH5-dependent sensitization to ABT-737 requires the presence of 
BAX 
WT, BAK-/-, BAX-/- and BAK/BAX DKO HCT116 cells were depleted of MARCH5 
and treated with ABT-737 (Black bar: DMSO, red: 5 µM, grey: 10 µM). Error bars 
represent the SD of triplicate measurements for each condition. Asterisks (***) 
indicate p values < 0.001 compared to the respective controls using Student’s t-test. 
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MARCH5 regulates the stability of MCL1 
 
ABT-737 can antagonize BCL2, BCLXL, and BCLW, but not MCL1. Thus many tumors 
are refractory to ABT-737 treatment as they express high levels of MCL1. In vitro studies 
have shown that such tumors can be re-sensitized to ABT-737 following siRNA-mediated 
MCL1 knockdown151. Given that MARCH5 also sensitizes to ABT-737, we speculated 
that MARCH5 and MCL1 might exhibit a functional interaction. Since MARCH5 loss 
sensitized to ABT-737, which is blocked by high MCL1 expression, we initially 
hypothesized that MARCH5 depletion would engender a reduction of MCL1 level. 
Strikingly, however, loss of MARCH5 led to a robust stabilization of MCL1 (Fig. 3.4a). 
This effect was specific, as the levels of other anti-apoptotic proteins did not change upon 
depletion of MARCH5 (Fig. 3.4a). The stabilization of MCL1 was post-translational, as 
MCL1 mRNA was unchanged following MARCH5 loss (Fig. 3.4b). 
To further characterize the stabilization of MCL1, cycloheximide pulse chase experiments 
were performed on U2OS and HCT116 cell lines following transfections with siRLUC or 
siMARCH5. The depletion of MARCH5 led to prolonged stabilization of MCL1 in 
contrast to its normal turnover rate as observed in the control (Fig. 3.4c). 
In line with these observations, the overexpression of MARCH5 led to the destabilization 
of MCL1 protein and this effect could be rescued through the addition of a proteasomal 
inhibitor, MG132 (Fig. 3.4d). Together, these data suggest that MARCH5 controls MCL1 
levels by regulating its proteasome-dependent degradation.  
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Figure 3.4.  MARCH5 regulates MCL1 stability 
(a) Lysates from HCT116 cells transfected with control siRNA or siRNA targeting 
MARCH5 were subjected to SDS-PAGE and western blotting.  
(b)  MCL1 mRNA levels were measured following MARCH5 knockdown using 
quantitative RT-PCR and were normalized to 18S mRNA. Error bars indicate 
the SD of triplicate measurements.  
(c)  Cycloheximide pulse-chase experiments were performed by treating 
transfected cells with cycloheximide for the given time points. Lysates were 
subjected to SDS-PAGE and immunoblot analysis to observe MCL1 stability. 
Graphs show MCL1 protein band intensities normalized to the loading control. 
(d) U2OS cells expressing doxycycline-inducible FLAG-MARCH5 were treated 
with 50 ng/ml doxycycline for 24 h and with 10 μM MG132 for 3 h. Whole cell 
lysates were subjected to SDS-PAGE and immunoblotted with the indicated 
antibodies. 
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MARCH5 regulates MCL1 ubiquitination 
In order to assess whether MARCH5 regulates MCL1 ubiquitination, doxycycline-
inducible MARCH5WT and MARCH5C65SC68S (ligase defective mutant) expressing cells 
were transfected with HA-ubiquitin. MARCH5WT expressing cells were also treated with 
MG132 in order to block the degradation of MCL1 upon the overexpression of MARCH5. 
Less MCL1 was co-immunoprecipitated with HA-ubiquitin following overexpression of 
MARCH5C65SC68S as compared to MARCH5WT treated with proteasome inhibitor (Fig. 3.5). 
These data indicate that MCL1 ubiquitination is controlled by MARCH5 ligase activity 
and that the MARCH5C65SC68S mutant stabilizes MCL1 by preventing its ubiquitination. 
The MARCH5C65SC68S appears to function as a dominant-negative (i.e., it likely inhibits the 
function of the endogenous wild-type MARCH5). 
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Figure 3.5. MARCH5 regulates MCL1 ubiquitination 
Whole cell lysates from U2OS cells stably expressing doxycycline-inducible 
FLAG-MARCH5WT or FLAG- MARCH5C65SC68S transfected with the indicated 
plasmids and treated with Doxycyline (50 ng/ml) and/or MG132 (10 μM) as 
shown were subjected to immunoprecipitation using anti-HA antibody. 
Immunoprecipitated complexes were then subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. Input blots represent levels of 
indicated proteins in the whole cell lysate. 
 
Loss of MARCH5 promotes transcriptional upregulation of p53 targets 
Having observed a paradoxical stabilization of the anti-apoptotic protein, MCL1, we 
reasoned that MARCH5 loss might also promote up-regulation of pro-apoptotic proteins. 
This would counter the increase in MCL1 levels, and would reconcile our findings of 
increased sensitivity to ABT-737 under these conditions. Since the p53 tumor suppressor 
can modulate ABT-737-induced cell death152, we therefore examined the levels of p53 and 
its downstream transcriptional targets. Quantitative PCR and western blotting showed that 
p53 and several of its targets are upregulated in MARCH5 knockdown cells compared to 
control (Fig. 3.6 a, b).  
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Figure 3.6. MARCH5 loss leads to increased expression of p53 targets 
(a)  The expression of p53 targets-PUMA and p21 following MARCH5 knockdown    
in HCT116 cells were assessed by quantitative RT-PCR. Error bars indicate the 
SD of triplicate measurements.  
(b) Whole cell lysates from control or MARCH5-depleted HCT116 cells were 
subjected to SDS-PAGE and immunoblotted with the indicated antibodies. 
 
Sensitization to apoptosis upon MARCH5 loss is partially p53-dependent 
Given that p53 targets were upregulated upon MARCH5 loss, experiments were performed 
to assess whether the sensitization to ABT-737 in the absence of MARCH5 was p53-
dependent. Isogenic HCT116 p53WT and HCT116 p53-/- cell lines were transfected with 
siMARCH5 and treated with ABT-737. The absence of p53 ameliorated the enhanced cell 
death observed upon MARCH5 loss and ABT-737 treatment although some sensitization 
was observed at higher concentrations of the compound (Fig. 3.7a, b).  
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Figure 3.7. MARCH5 depletion sensitizes cells to apoptosis in a largely p53-
dependent manner 
(a) Isogenic HCT116 p53WT and HCT116 p53-/- cells were transfected with 
control siRNA or siRNA targeting MARCH5 and treated with ABT-737 at 
the indicated concentrations. Cell viability was measured using CellTiter-
Glo. Error bars represent the SD of triplicate experiments. Asterisks (***) 
indicate p values <0.001 compared to the respective controls using 
Student’s t-test. No significant difference represented by (ns).  
(b) Isogenic HCT116 p53WT and HCT116 p53-/- cells were transfected with 
control siRNA or siRNA targeting MARCH5 and treated with ABT-737 at 
the indicated concentrations. Whole cell lysates were harvested and 
subjected to SDS-PAGE and immunoblotted with the indicated antibodies. 
PARP cleavage was quantified as the ratio of cleaved to full length PARP. 
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BH3 profiling reveals that NOXA is an essential mediator of apoptosis 
following MARCH5 loss 
In order to functionally dissect the BCL-2 pathway downstream of MARCH5, BH3 
profiling was performed through genetic studies using isogenic cell lines or RNAi. PUMA, 
BIM, and NOXA are BH3-only “de-repressor” pro-apoptotic proteins that are responsible 
for the inhibition of the anti-apoptotic BCL-2 family members or for the direct activation 
of BAX and BAK26. Experiments with the isogenic cell lines HCT116 PUMAWT and 
HCT116 PUMA-/- revealed that PUMA was dispensable for the sensitization to apoptosis 
upon MARCH5 loss (Fig. 3.8a). Similar experiments were performed using siRNA to 
target BIM and NOXA in order to determine which of these proteins was required for cell 
death following MARCH5 knockdown. The loss of NOXA (but not BIM) specifically 
abrogated sensitization to ABT-737 (Fig. 3.8b, c). 
a 
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Figure 3.8. Sensitization to apoptosis upon MARCH5 loss is dependent on the BH3-
only protein NOXA 
(c) Isogenic HCT116 PUMAWT and HCT116 PUMA-/- cells were transfected 
with control siRNA or siRNA targeting MARCH5 and treated with ABT-
737 at the indicated concentrations. Cell viability was measured using 
CellTiter-Glo. Error bars represent the SD of triplicate experiments. ‘ns’ 
represents no significant difference between the levels of sensitization 
through combined MARCH5 loss and ABT-737 treatment in the two cell 
lines. Isogenic HCT116 PUMAWT and HCT116 PUMA-/- cells were 
transfected with control siRNA or siRNA targeting MARCH5 and treated 
with ABT-737 at the indicated concentrations. Whole cell lysates were 
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harvested and subjected to SDS-PAGE and immunoblotted with the 
indicated antibodies. PARP cleavage was quantified as the ratio of cleaved 
to full length PARP. 
(d) HCT116 cells transfected with siRLUC, siMARCH5, siNOXA or co-
transfected with siMARCH5/siNOXA were treated with ABT-737 (Black 
bar: DMSO, red: 5 µM, grey: 10 µM). Cell viability was assessed using 
CellTiter-Glo. Error bars represent the SD of triplicate experiments. 
Asterisks (***) indicate p values <0.001 compared to the respective 
controls using Student’s t-test. No significant difference represented by (ns). 
Whole cell lysates were harvested and subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. PARP cleavage was 
quantified as the ratio of cleaved to full length PARP. 
(e) HCT116 cells transfected with siRLUC, siMARCH5, siBIM or co-
transfected with siMARCH5/siBIM were treated with ABT-737 (Black bar: 
DMSO, red: 5 µM, grey: 10 µM). Cell viability was assessed using 
CellTiter-Glo. Error bars represent the SD of triplicate experiments. 
Asterisks (***) indicate p values <0.001 compared to the respective 
controls using Student’s t-test. No significant difference represented by (ns). 
Whole cell lysates were harvested and subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. PARP cleavage was 
quantified as the ratio of cleaved to full length PARP. 
(f) Validation of knockdown was performed by quantitative RT-PCR and 
mRNA levels were normalized to 18S mRNA 
 
 
67 
 
MARCH5 loss leads to stabilization of MCL1 in a                                 
NOXA-dependent manner 
Since the loss of MARCH5 led to stabilization of MCL-1 and still sensitized cells to BH3 
mimetics, we reasoned that one of the BH3- only proteins might be responsible for 
neutralizing MCL1’s anti-apoptotic activity. Two BH3-only proteins BIM and NOXA 
have been reported to bind to and inhibit MCL1153,43. To determine which of these proteins 
was required for stabilization, we knocked down MARCH5 in the presence and absence of 
siRNA to BIM or NOXA. Following MARCH5 loss, the knockdown of BIM had no 
effects on MCL1 levels (Fig. 3.9).  The loss of NOXA alone led to a slight stabilization of 
MCL1, as reported in prior studies154. However, the concomitant loss of NOXA and 
MARCH5 attenuated the induction of MCL1 that we observed upon MARCH5 knockdown (Fig. 
3.9). Validation of knockdown was performed using qRT-PCR (Fig. 3.8d) 
 
Figure 3.9. MARCH5-dependent stabilization of MCL1 requires NOXA 
Whole cell lysates from HCT116 cells transfected with siRLUC, siMARCH5, 
siBIM, siNOXA, or co-transfected with siMARCH5/siBIM and 
siMARCH5/siNOXA were subjected to SDS-PAGE and immunoblotted with the 
indicated antibodies. 
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Depletion of MARCH5 leads to stabilization of NOXA in a p53-
independent manner 
Having observed a NOXA-dependent induction of apoptosis and the stabilization of   
MCL1 upon MARCH5 loss, we surmised that the loss of MARCH5 promotes up 
regulation of NOXA. Quantitative real-time PCR revealed that MARCH5 depletion did not 
affect NOXA at the transcriptional level (Fig. 3.8d). However, a robust stabilization of 
NOXA protein was observed in the absence of MARCH5 (Fig. 3.10a and Fig. 3.8b). 
Interestingly, the loss of NOXA promoted a destabilization of MARCH5 protein, 
indicating some level of co-regulation between these two proteins (Fig. 3.10a). This will be 
further addressed in the Discussion. 
Since NOXA is a p53 transcriptional target, we formally excluded a role for induction of 
NOXA mRNA by using isogenic HCT116 p53WT and HCT116 p53-/- cell lines. This 
demonstrated that both NOXA and MCL-1 were stabilized in both genetic backgrounds 
upon MARCH5 loss. However, the absolute level was lower in the HCT116 p53-/- cells 
than that observed in HCT116 p53WT (Fig. 3.10b).  
a 
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Figure 3.10. MARCH5 loss stabilizes NOXA 
(a) Whole cell lysates from HCT116 cells transfected with siRLUC, siMARCH5, 
siNOXA, or co-transfected with siMARCH5/siNOXA were subjected to SDS-
PAGE and immunoblotted with the indicated antibodies. 
(b) HCT116 p53WT and HCT116 p53-/- cells were transfected with control siRNA or 
siRNA targeting MARCH5. Lysates were then subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. NOXA band intensities were 
quantified in HCT116 p53WT and HCT116 p53-/- cells. Error bars are SD of three 
independent experiments. 
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A MARCH5 ligase-deficient mutant promotes concomitant upregulation 
of MCL1 and NOXA 
MARCH5 depletion led to the stabilization of MCL1 and NOXA; it was therefore 
surmised that loss of MARCH5 E3 ubiquitin ligase activity underpinned this observation. 
In order to test this, cell-based assays were also performed using doxycycline inducible 
MARCH5WT and a ligase-deficient MARCH5C65SC68S (CS). As shown in Fig. 3.11a, the 
overexpression of MARCH5WT reduced endogenous MCL1 levels, whereas MARCH5CS 
stabilized both MCL1 and NOXA (Fig. 3.11a). Interestingly, overexpression of this mutant 
also stabilized endogenous MARCH5 (Fig. 3.11a). This could be since it interacts with the 
endogenous form, thereby not only preventing its degradation, but also rendering it 
functionally inactive. 
In order to assess the importance of NOXA in the MARCH5-dependent degradation of 
MCL1, U2OS cells expressing doxycycline-inducible MARCH5WT and MARCH5CS were 
transfected with control siRNA (siRLUC) or siRNA targeting NOXA. The expression of 
FLAG- MARCH5 was induced and the levels of MCL1 were assessed in the presence and 
absence of NOXA. The depletion of NOXA abrogated the MARCH5-dependent 
degradation of MCL1 (compare lanes 2 and 7). Interestingly, the loss of NOXA also 
inhibited the stabilization of MCL1 observed with the expression of MARCH5CS (Fig. 
3.11b). This recapitulated the earlier results in the RNAi experiments where concomitant 
depletion of MARCH5 and NOXA abrogated MCL1 stabilization. 
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Figure 3.11. NOXA is required for the regulation of MCL1 by MARCH5 
(a) U2OS cells stably expressing doxycycline-inducible FLAG-MARCH5WT or FLAG- 
MARCH5C65SC68S were induced with 50 ng/ml doxycyline for 24 h. Whole cell 
lysates were then subjected to SDS-PAGE and immunoblotted with the indicated 
antibodies. 
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(b) U2OS cells stably expressing doxycycline-inducible FLAG-MARCH5WT or FLAG- 
MARCH5CS were transfected with control siRNA or siRNA targeting NOXA. 
Twenty-four hours post transfection, the cells were treated with 50 ng/ml 
doxycycline for a further 24 h to induce the expression of FLAG-MARCH5. Cells 
expressing FLAG-MARCH5WT were also treated with MG132 for 3 h to block the 
proteasomal degradation of MCL-1. Whole cell lysates were harvested, subjected to 
SDS-PAGE, and immunoblotted with the indicated antibodies. 
Knockdown of NOXA mRNA in U2OS FLAG-MARCH5WT and FLAG- 
MARCH5CS was assessed by quantitative RT-PCR. Error bars indicate the SD of 
triplicate measurements. 
 
MARCH5 RING domain mutant sensitizes cells to ABT-737 in a                          
NOXA-dependent manner 
The expression of MARCH5CS promoted concomitant stabilization of MCL1 and NOXA, 
which recapitulates the phenotype observed with MARCH5 siRNA. Since the co-
stabilization was critical for mediating sensitivity to ABT-737, we thus hypothesized that 
expression of MARCH5CS should also sensitize to ABT-737. U2OS cells expressing 
doxycycline-inducible MARCH5WT and MARCH5CS were transfected with control siRNA 
(siRLUC) or siRNA targeting NOXA.  When compared to the non-induced (-DOX) 
control, the expression of MARCH5CS sensitized cells to the BH3 mimetic. In contrast, the 
absence of NOXA completely ameliorated this effect (Fig. 3.12). The overexpression of 
MARCH5WT had no significant effect on ABT-737-induced cell death, and was similar to 
the –DOX control. The lack of protection by the wild-type MARCH5 may be attributed to 
the absence of NOXA stabilization (), which appears critical for response to ABT-737.  
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Figure 3.12. Sensitization to ABT-737 via a RING domain mutant of MARCH5 is 
abrogated upon depletion of NOXA 
U2OS cells stably expressing doxycycline-inducible FLAG-MARCH5WT or 
FLAG- MARCH5CS were transfected with control siRNA or siRNA targeting 
NOXA. Twenty-four hours post transfection, the cells were treated with 50 
ng/ml doxycycline to induce the expression of FLAG-MARCH5 and with 
ABT-737 (Black bar: DMSO, red: 5 µM, grey: 10 µM). Cell viability was 
assessed using CellTiter-Glo. Error bars represent the SD of triplicate 
measurements. Asterisks (***) represent a p value < 0.001 compared to the 
respective controls using Student’s t-test. 
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MARCH5-dependent regulation of MCL1 stability and sensitivity to 
ABT-737 relies on direct MCL1-NOXA interaction 
We observed a dependency on NOXA for MARCH5-mediated regulation of MCL1 
stability and sensitization to ABT-737. However, it was unclear whether these effects 
required direct interactions between NOXA and MCL1.  
In order to assess this question, HeLa cells expressing doxycycline-inducible NOXAWT or 
NOXAL29E (a NOXA BH3 domain mutant that cannot interact with MCL1)154 were 
transfected with siRLUC, siMARCH5. This was followed by induction of ectopic 
expression of NOXAWT or NOXAL29E. 
The induction of NOXAWT following MARCH5 depletion elicited robust stabilization of 
MCL1. This is in line with our results that increased NOXA expression in required for the 
MARCH5-dependent stabilization of MCL1. In contrast, the expression of NOXAL29E 
significantly attenuated the stabilization of MCL1 upon MARCH5 loss (Fig. 3.13b). This 
suggests that direct interaction between the NOXA BH3 domain and MCL1 is required for 
MARCH5-dependent regulation of MCL1 (see model Figure in Discussion). NOXAL29E 
itself appeared to be more stable than NOXAWT. This indicates that, in addition to 
mediating interactions between NOXA and MCL1, the BH3 domain is also required for the 
normal turnover of NOXA.  
Interestingly, the exprssion of NOXAWT was not toxic in the absence of ABT, but became 
so when MARCH5 was concomitantly knocked down (Fig. 3.13a), and this correlated with 
increased levels of NOXA (Fig. 3.13b). Furthermore, MARCH5-dependent sensitization to 
ABT-737 was enhanced following induction of NOXAWT, but was completely abrogated in 
the presence of NOXAL29E (Fig. 3.13a). Importantly, the MCL1 stabilization accompanying 
MARCH5 loss was also attenuated in the presence of NOXAL29E.This phenocopies the 
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results of the NOXA siRNA experiments described above. Together, these data reveal a 
direct role for NOXA in the inactivation of MCL1 following loss of MARCH5.  
a                                                                                   b                 
                        
                                                                                                          
Figure 3.13. MARCH5-dependent regulation of MCL1 and sensitivity to ABT-737 
requires direct MCL1/ NOXA interactions 
(a) Doxycycline-inducible HeLa cells expressing either NOXAWT or NOXAL29E 
were transfected with the indicated siRNAs. Ectopic expression of NOXA 
or its mutant form was induced for 48 h. Cells were then harvested and 
plated on 96-well plates. Cells were treated with ABT-737 at the indicated 
concentrations for 24 h. Cell viability was assessed using CellTiter-Glo. 
Error bars represent the SD of triplicate measurements. Asterisks (***) 
represent a p value < 0.001 compared to the respective controls using 
Student’s t-test. 
(b) Whole cell lysates were subjected to SDS-PAGE and immunoblotted with 
the indicated antibodies. 
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Dissection of MARCH5-dependent synthetic lethal interactions using 
selective BH3 mimetics 
Our observations thus far with ABT-737 demonstrate a MARCH5-dependent chemical-
genetic lethal interaction with the BCL2 pathway. Since ABT-737 inhibits BCL2, BCLXL, 
and BCLW, this compound cannot be used to determine the relative contribution of each 
anti-apoptotic protein to the sensitization observed. To address this, we used specific BCL-
2 antagonists that were developed during the course of our studies49,155.  
Synthetic lethality was observed with MARCH5 knockdown in the presence of the 
BCLXL-selective antagonist, WEHI-539, but not with ABT-199, a BCL2-selective 
antagonist (Fig. 3.14a, b). This result was further validated by concomitantly knocking 
down MARCH5 and BCL2 through RNAi (data not shown). Cumulatively, these data 
therefore indicate that although the loss of MARCH5 leads to the functional inactivation of 
MCL1 by NOXA, BCLXL can act as a “backup” and enable the survival of HCT116 cells.  
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Figure 3.14. MARCH5 loss displays synthetic lethality with the BCLXL-specific 
antagonist, WEHI-539 
(a) HCT116 cells transfected with siRNAs targeting luciferase or MARCH5 were 
treated with WEHI-539 at the indicated concentrations. Cell viability was measured 
using CellTiter-Glo. The error bars represent the SD from triplicate measurements 
for each condition. The asterisks (***) indicate a p value of < 0.001 compared to 
the respective controls using Student’s t-test. 
(b) HCT116 cells transfected with the indicated siRNAs were treated with ABT-199 at 
the given concentrations. Cell viability was measured using CellTiter-Glo. The 
error bars represent the SD from triplicate experiments. 
 
Synthetic lethality of MARCH5 and MCL1 in MCL1-dependent            
breast cancer 
Given our observations of a MARCH5/MCL1 link, we asked whether (independently of 
the chemical genetic interactions) a synthetic lethal relationship might exist between these 
two genes. This was not observed in HCT116 cells (Fig. 3.15b); however, chemical and 
genetic inhibition of MCL1 in HCT116 revealed that they are not dependent on MCL1, at 
least in these short-term assays (Fig. 3.15a, b). It was therefore hypothesized that 
MARCH5 loss would exhibit synthetic lethality in cell lines that are known to be MCL1-
dependent.  To this end, two triple negative breast cancer lines, MDA-MB-231 and MDA-
MB-468 that differ with regard to their dependence on MCL1 were selected156. Using the 
MCL1 specific inhibitor A1210477, it was confirmed that the MDA-MB-468 cells were 
indeed MCL1-dependent, whereas the MDA-MB-231 line was not dependent on MCL1 for 
survival (Fig. 3.15a). This is consistent with previous studies, and was further validated 
using MCL1 RNAi (Fig. 3.15c).  
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Strikingly, concomitant loss of MARCH5 and MCL1 was synthetic lethal in the MCL1 
dependent MDA-MB-468 cell line, but not in the MCL1 independent line MDA-MB-231 
(Fig. 3.15c).  
Interestingly, both these cells lines harbor inactive p53 mutant proteins 
(http://p53.free.fr/Database/p53_database.html). Consistent with their p53 status and with 
prior results in the isogenic HCT116WT and HCT116p53-/- cells (Fig. 3.7), the loss of 
MARCH5 did not sensitize these cells to ABT-737 (Fig. 3.15d). These results validate our 
earlier observations and emphasize the importance of p53 in the MARCH5-dependent 
sensitization to ABT-737.  
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Figure 3.15. Concomitant loss of MARCH5 and MCL1 is synthetic lethal in MCL1 
driven breast cancer lines.  
(a) HCT116, MDA-MB-231 and MDA-MB-468 were treated with the MCL1-specific 
inhibitor, A1210477 at the indicated concentrations. Cell viability was measured 
using CellTiter-Glo. Error bars represent the SD from triplicate measurements. 
(b) HCT116 cells were depleted of MARCH5 or MCL1 or co-depleted of MARCH5 
and MCL1. Cell viability was measured using CellTiter-Glo. Error bars represent 
the SD of triplicate experiments. Ns represents no significant difference. 
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(c)  MDA-MB-231 and MDA-MB-468 cells were depleted of MARCH5 or MCL1 or 
co-depleted of MARCH5 and MCL1. Cell viability was measured using CellTiter-
Glo. Error bars represent the SD of triplicate experiments. The asterisks (**) and 
(***) indicate p values of <0.01 and <0.001 respectively compared to respective 
controls using Student’s t-test. No significant difference is represented by ns.  
(d) MDA-MB-231 and MDA-MB-468 cells were transfected with control siRNA or 
siRNA targeting MARCH5 and treated with ABT-737 (Black bar: DMSO, red: 5 
µM, grey: 10 µM). Cell viability was assessed using CellTiter-Glo. Error bars 
represent the SD of triplicate experiments. No significant difference compared to 
respective controls is represented as ‘ns’ and was derived by using Student’s t-test. 
(e) Validation of knockdown was performed by quantitative RT-PCR and mRNA 
levels were normalized to 18S mRNA. 
 
Sensitization to ABT-737 upon MARCH5 loss is similar to that 
achieved with a direct chemical inhibitor of MCL1 
During the course of this study, breakthroughs in the design of MCL1-specific 
inhibitors have been made. One specific compound, A1210477 has shown great 
promise in targeting MCL1-dependent tumors as a single agent or in combination with 
ABT-263 (Navitoclax) in other cell lines157. Since we observed similar effects upon 
loss of MARCH5, we wanted to compare the effect of MCL1 functional inhibition 
achieved by MARCH5 loss with that obtained using a direct chemical inhibitor of 
MCL1.  
In line with this, (Fig. 3.15a) shows that treatment with A1210477 alone induced death 
in MCL1-dependent breast cancer cell lines but not in HCT116 cells, which are not 
dependent on MCL1. Combined treatment with high doses of ABT-737 and A1210477 
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induced cell death in HCT116 cells (Fig. 3.16a). This, however, was no more effective 
than a combination of ABT-737 and MARCH5 depletion (Fig. 3.16b). Therefore, the 
functional inhibition of MCL1 achieved by depleting MARCH5 is sufficient to induce 
the same response as through direct targeting of MCL1. 
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Figure 3.16.  MARCH5-dependent sensitization to ABT-737 is comparable to 
combined treatment with ABT-737 and A1210477 
(a) HCT116 cells were treated with ABT-737 and A1210477 either alone or in 
combination at the indicated concentrations. Cell viability was measured using 
CellTiter-Glo. Error bars represent the SD of triplicate measurements. 
(b)  HCT116 cells were transfected with control siRNA or siRNA targeting MARCH5 
and treated with ABT-737 (Black bar: DMSO, red: 5 µM, grey: 10 µM) or treated 
with a combination of ABT-737 and A1210477. Cell viability was measured using 
CellTiter-Glo. Error bars represent the SD of triplicate measurements. The asterisks 
(***) indicate p values of < 0.001 compared to combination treatment of ABT-737 
and A1210477 using Student’s t-test. 
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MARCH5 contributes to a gene signature associated with                        
ABT-263 sensitivity 
Several factors in addition to MCL1 are associated with sensitivity to BH3 mimetics158,156. 
A strong prediction from the biological data in this study is that MARCH5 expression may 
also contribute to the response to ABT-737.  
Using a publicly available dataset, multiple linear regression analyses were performed in 
order to determine whether expression of MARCH5 mRNA (alone or in combination with 
selected other factors) was predictive of ABT-737 sensitivity. Together with MARCH5, 
other proteins such as BAX and BAK (since they are terminal effectors of the response to 
ABT-737), NOXA and BCL2L1/BCLXL (based on our current data), BCL2L11/BIM (as it 
is implicated in the response to ABT-737), and MCL1 (a well-documented determinant of 
sensitivity to ABT-737) were selected. HUWE1, an MCL1 ubiquitin ligase that can 
accelerate BH3-dependent apoptosis was also selected32. The stratification of the groups 
based on p53 status was also performed, since p53 can contribute to BH3 mimetic-induced 
death. 
Fig. 3.17a shows the results of an optimized multiple linear regression model. Consistent 
with their known influence on ABT-737 sensitivity, expression of BAX, HUWE1, and 
NOXA were significant contributors to the gene signature in cells expressing either wild 
type or nonfunctional p53 (this latter group includes both p53 mutations and deletions).  
Interestingly, MCL1 expression was a strong determinant of the ABT-737 sensitivity of 
cells expressing mutant p53. By contrast, the effect of MCL1 in cells with wild type p53 
was much weaker. This underscores the finding that the level of MCL1 expression alone is 
not always sufficient to predict ABT-737 sensitivity , and also suggests that other p53-
induced factors can to some extent attenuate the anti-apoptotic function of MCL1159.  
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Although the biological data in this study show that MARCH5 is a clear modulator of the 
ABT-737 response, its expression was not identified as a significant determinant of 
sensitivity in the multiple regression analysis. However, since the analysis was performed 
on a large cohort of cell lines from diverse tumor types, it was reasoned that re-analysis 
based on tissue of origin might provide further insight. Therefore, data from all wild type 
p53 cell lines was compared to the data from the hematological malignancies (blood) 
subset.  
This choice was based on evidence from both cell-based and preclinical animal models that 
individuals with liquid tumors comprise a suitable target population for BH3 mimetic 
treatment.  As expected, the pro-apoptotic effectors BAX and BAK were associated with 
increased ABT-737 sensitivity in these malignancies (Fig. 3.17b). Strikingly, both 
MARCH5 and MCL1 were significantly associated with the ABT-737 sensitivity of the 
blood subset (Fig. 3.17b). Fig. 3.17c is a graphical representation of the contribution of 
these four genes to ABT-737 sensitivity, clearly indicating that MARCH5 and MCL1 
expression were inversely correlated with ABT-737 sensitivity, whereas BAX and BAK 
were associated with increased sensitivity. Together with the experimental data, this 
analysis suggests that MARCH5 is a context-dependent modulator of the sensitivity to 
BH3 mimetics. 
Intriguingly, the optimized model also identified pairwise combinations among these  
genes that contribute to sensitivity.   For   example,   co-regulation   of   
MARCH5/NOXA and  MARCH5/BAX  were  significant  factors  that  may  
contribute  to  the  BH3 mimetics response (refer to Appendix I). 
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Figure 3.17. Expression of MARCH5 and MCL1 are significant contributors to a gene 
signature predicting sensitivity to navitoclax  
(a)  Contribution of each gene to  the  multiple  linear  regression  analysis  of  an  8-
gene  expression  profile   and navitoclax sensitivity across a panel of 648 cell 
lines (221 wild type p53, 427 non-functional p53). Green circles p < 0.05; Red 
circles, ns. The size of the circle is proportional to the effect size and the 
estimated effect size is enumerated below the circles.  For example, MCL1 
expression had the greatest influence on navitoclax sensitivity in the p53 
MUT/DEL cell lines, whereas its   effect was smaller and not significant in p53 
WT cell lines.  
(b)   Comparison of the contribution of each gene to the sensitivity profiles of all 
tumor lines with wild type p53 versus the ‘blood only’ subset. Green circles p < 
0.05; Red circles, ns. The size of the circle is proportional to the effect size. 
(c) Relationship  between  navitoclax  sensitivity     and expression of the four genes 
that significantly contribute to the sensitivity profile of the  ‘Blood  p53  WT’  
subset  (corresponding  to  green  circles  in  panel  B).  Each datapoint represents 
one cell line. Values on the y-axis (IC50*) are regression-adjusted IC50   
values.   Values on the x-axis are regression-adjusted mRNA expression levels. 
Estimate values are derived from slope of the regression line and reflect the effect 
size. 
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(II) MARCH5 REGULATES MITOCHONDRIAL 
MORPHOLOGY 
 
Loss of MARCH5 promotes accumulation of perinuclear mitochondria 
MARCH5 has been previously identified as a regulator of mitochondrial dynamics through 
the modulation of the levels or activity of the pro-fusion GTPases, MFN1/2 and the pro-
fission DRP1 GTPase134,137,139,160. Changes in mitochondrial morphology also dictate the 
response to chemotherapeutics161. Thus, we wanted to assess if changes in mitochondrial 
morphology due to loss of MARCH5 might contribute to the results described above (i.e., 
namely MCL1 stabilization and sensitization to apoptosis). 
In order to assess whether MARCH5 loss led to changes in mitochondrial morphology, 
U2OS cells were depleted of MARCH5 and mitochondria were stained with an antibody 
against TOMM20, a marker of the mitochondrial outer membrane. The loss of MARCH5 
led to the collapse of the mitochondrial network and accumulation of perinuclear 
mitochondria (Fig. 3.18a). These changes in morphology were quantified by segmenting 
for cell possessing perinuclear mitochondria; samples depleted of MARCH5 showed a 
significantly higher percentage of cells possessing perinuclear mitochondria as compared 
to control (Fig. 3.18b).  
The collapse of the mitochondrial network and accumulation of perinuclear mitochondria 
has been associated with the presence of damaged and dysfunctional mitochondria that 
have reduced or altered mitochondrial membrane potential162. In order to assess whether 
MARCH5 loss led to reduction in mitochondrial membrane potential, cells depleted of 
MARCH5 were stained with the mitochondrial dye, TMRE. Depolarized or inactive 
mitochondria have decreased membrane potential and fail to sequester TMRE. Cells 
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transfected with siMARCH5 displayed lower levels of TMRE accumulation compared to 
RLUC controls suggesting that MARCH5 depletion leads to loss of mitochondrial 
membrane potential (Fig. 3.18c).  
Increased production of ROS and disrupted calcium homeostasis often accompany 
alterations in mitochondrial membrane potential. This in turn has important implications in 
stress-related signaling pathways including apoptosis163. Therefore the loss of 
mitochondrial membrane potential upon MARCH5 depletion could induce a cellular stress 
response that “primes” cells to undergo apoptosis. 
a 
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Figure 3.18. Loss of MARCH5 promotes accumulation of perinuclear mitochondria 
and loss of mitochondrial membrane potential 
(a) U2OS cells were plated on coverslips and transfected with siRLUC or siMARCH5 
for 72 h. Cells were then fixed in 4% paraformaldehyde and immunostained with 
anti-TOMM20 to stain mitochondria and DAPI for nuclear staining. Scale bars 
represent 10 μm. 
(b) U2OS were plated on 96-well plates following transfection with siRLUC or 
siMARCH5. Cells were then fixed in 4% paraformaldehyde and immunostained 
with anti-TOMM20 to stain mitochondria and DAPI for nuclear staining. 
Segmentation was performed for both nuclei and perinuclear mitochondria. 
Number of cells scored per well >300 for triplicate wells per condition. 
(c) U2OS cells were plated on 96-well plates following transfection with siRLUC or 
siMARCH5 and stained with TMRE. Nuclei were stained with Hoechst and live 
cell imaging was performed. Nuclear and cytoplasmic regions were defined during 
image segmentation and TMRE intensity was quantified. Number of cells scored 
per well >300 for six wells per condition. 
 
MARCH5 mutants alter mitochondrial morphology 
Given the importance of MARCH5 in the regulation of mitochondrial morphology, it was 
predicted that mutations in critical functional residues of MARCH5 could contribute to 
altered mitochondrial morphology. To this end, a panel of MARCH5 mutants were 
generated through site-directed mutagenesis. These mutants included two RING domain 
mutants- MARCH5H43W and MARCH5CS (Fig. 3.19a), and three ligase-defective constructs 
with mutations on hydrophobic patch residues suggested to be critical for E2 enzyme 
binding (MARCH5V16A, MARCH5V51A, and MARCH5P66A) (Fig. 3.19a). In addition, a 
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survey of the COSMIC database revealed a number of somatic mutations associated with 
several solid tumors. Of note, the D202 residue (which is located within a cytoplasmic-
facing loop) was mutated in independent patient samples, suggesting it may have 
functional relevance (ref). Thus, we generated MARCH5D202Y and MARCH5D202G mutants 
in order to understand their contribution to mitochondrial morphology.  
As seen in Fig. 3.19b, the expression of all MARCH5 mutants except MARCH5V51A 
elicited dramatic changes in mitochondrial morphology. Specifically, these mutants 
engendered high levels of fused mitochondria as compared to expression of MARCH5WT 
(Fig. 3.19b). Although the mutant forms of MARCH5 predominantly localized to the 
mitochondrial outer membrane as seen by co-localization with TOMM20, some 
submitochondrial species were observed. This is consistent with prior studies reported by 
Karbowski and colleagues (2007)134. This in part could be explained by the increased 
stability of the mutants compared to MARCH5WT and formation of higher order oligomers, 
which are indicative of defective turnover of the mutant proteins (Fig. 3.19c). 
a 
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Figure 3.19. MARCH5 mutants alter mitochondrial morphology 
(a) Schematic representation of conserved functional residues in MARCH5 
(b) U2OS cells were plated on coated coverslips and transfected with the indicated 
FLAG-MARCH5 constructs for 48 h. Cells were then fixed in 4% 
paraformaldehyde and immunostained with anti-TOMM20 to stain mitochondria, 
anti-FLAG to stain MARCH5 and DAPI for nuclear staining. Scale bars represent 
20 μm. 
(c) Whole cell lysates from U2OS cells transfected with the indicated constructs were 
subjected to SDS-PAGE and immunoblotted with the indicated antibodies. 
 
MCL1 stabilization occurs independently of changes in mitochondrial 
morphology 
We observed two different phenomena upon the loss of MARCH5. This included the 
stabilization of MCL1 and the accumulation of perinuclear mitochondria. In order to assess 
if the changes in mitochondrial morphology were related to the stabilization of MCL1, 
U2OS cells were treated with two compounds that induce identical perinuclear 
morphology to that observed in the absence of MARCH5. Treatment with CCCP (an 
uncoupler of oxidative phosphorylation)164 and mdivi-1 (a DRP1 inhibitor)91 did not affect 
MCL-1 levels despite inducing changes in mitochondrial morphology (Fig. 3.20).   
Together with our BH3 profiling results, these data indicate that MCL1 stabilization upon 
MARCH5 knockdown is mediated via regulation of NOXA, rather than by changes in 
mitochondrial morphology per se. 
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Figure 3.20. MCL1 stabilization occurs independent of changes in mitochondrial 
morphology 
(a)  U2OS cells were plated on coverslips and transfected with the siRLuc, siMARCH5 
for 72 h or treated with CCCP (5 μM) for 4 h and mdivi-1 (10 μM) for 48 h. Cells 
were then fixed in 4% paraformaldehyde and immunostained with anti-TOMM20 
to stain mitochondria and DAPI for nuclear staining. Scale bars represent 10 μm. 
(b)  Whole cell lysates from U2OS cells treated with CCCP and mdivi-1 at the 
indicated concentrations were subjected to SDS-PAGE and immunoblotted with the 
indicated antibodies. 
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CHAPTER 4. DISCUSSION 
Summary: Mitochondrial ubiquitin ligases and regulation of apoptosis 
At least four RING E3 ligases (MULAN, RNF144B, TRIM59, and MARCH5) are 
constitutively localized to the mitochondrial outer membrane.  MULAN is a regulator of 
mitochondrial morphology. In addition, during stress-induced mitochondrial hyperfusion, 
MULAN ubiquitinates TRAF2 to activate NF-ĸB signaling, possibly enabling cell survival 
under stress conditions127,165. In contrast, MULAN is also a negative regulator of AKT and 
suppresses its signaling by targeting phosphorylated AKT for degradation166. These 
opposing functions of MULAN may signify specific roles in different cellular contexts. 
RNF144B is a critical regulator of epithelial homeostasis and its over-expression reduced 
the stability of pro-apoptotic BAX, thus protecting cells from undergoing apoptosis124. 
TRIM59 can negatively regulate p53, and is upregulated in gastric tumours, suggesting that 
it may facilitate tumorigenesis167.  
Here, we demonstrate that MARCH5 is a regulator of sensitivity to the BH3-mimetic 
ABT-737, and that this occurs via NOXA-dependent functional inactivation of MCL1. 
This is, to the best of our knowledge, the first report of direct regulation of the 
NOXA/MCL1 axis by a mitochondrial ligase. Furthermore, it is the first clear 
demonstration that a member of the MARCH family can regulate intrinsic apoptosis. Our 
results provide a conceptual framework for follow-on studies to identify additional targets 
of mitochondrial ligases that may be involved in tumorigenesis or drug resistance. Below, 
the key results of this study are discussed in a wider context.   
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(i) MARCH5 and BCL-2 family-mediated apoptosis 
MARCH5 specifically and selectively interacts with members of the BCL-2 family of 
proteins, and these interactions determine the sensitivity to BH3 mimetics. 
Mechanistically, a NOXA/MCL1 axis is activated upon MARCH5 loss, and NOXA is 
required for both MARCH5-dependent stabilization of MCL1 as well as the enhanced 
BH3-dependent apoptosis. Notably, BIM and PUMA were dispensable for this response. 
Both these proteins are capable of binding and functionally inhibiting MCL1153,44,168; 
however, the MARCH5-dependent regulation of MCL1 specifically requires NOXA. 
The co-stabilization of NOXA and MCL1 following MARCH5 depletion appears 
paradoxical, as sensitization to ABT-737 has been associated with the NOXA-dependent 
degradation of MCL1. However, it is possible that following the loss of MARCH5, the 
increase in MCL1 levels serves as a protective mechanism that guards against apoptosis 
that would be otherwise induced by NOXA upregulation. This concomitant upregulation 
could provide a “decision” point for entry into apoptosis, which can be triggered by a shift 
in the stoichiometry of NOXA levels over MCL1 or by activation of additional pro-
apoptotic BH3 proteins by compounds such as ABT-737.  
In support of this concept, camptothecin (CPT) treatment of cancer cells leads to 
upregulation of both MCL1 and NOXA, yet the propensity to undergo apoptosis depends 
on the precise ratio between NOXA and MCL1 levels169. This phenomenon was also 
observed in small cell lung cancers where the NOXA/MCL1 axis was a critical 
determinant of ABT-737 sensitivity170. Furthermore, despite concomitant upregulation of 
NOXA and MCL1, squamous cell carcinomas retain sensitivity to ABT-737, since 
treatment with the drug increases the NOXA:MCL1 ratio171. 
 
NOXA is a critical regulator of MCL1 stability at the mitochondrial outer membrane, and 
the formation of a NOXA-MCL1 complex is reportedly essential for the initiation of 
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proteasome-dependent MCL1 degradation and apoptosis44,168. However, in this study, the 
enhanced stabilization of MCL1 upon MARCH5 loss was actually dependent on a 
concomitant increase in NOXA levels.  
 
These data clearly indicate that the proposed model in which NOXA upregulation leads to 
MCL1 degradation does not always hold true. We infer that the binding of NOXA via its 
BH3 domain serves to functionally inhibit MCL1. In support of this, there are reports that 
MCL1 is also stabilized by small molecule antagonists that bind to the same region of 
MCL1 as NOXA157. 
 
Apart from the requirement for NOXA during MARCH5-dependent regulation of MCL1, 
we also observed that the depletion of NOXA alone can moderately stabilize MCL1. 
Interestingly, this was accompanied by a destabilization of MARCH5. This is reminiscent 
of our RNAi data, where the loss of MARCH5 led to stabilization of MCL1. It is therefore 
apparent that MCL1 stability is tightly controlled by the levels of MARCH5, and that 
NOXA is critical for this regulation.  It is probable that these three proteins exist in a 
complex at the mitochondria and changes in levels of one of the proteins impacts the 
stability of the others. This represents a novel mechanism by which a mitochondrial protein 
interacts with two BCL-2 family members in order to regulate their stability and function. 
 
We observed a decrease in MCL1 ubiquitination upon expression of a ligase-defective 
MARCH5, suggesting that MARCH5 may be an MCL1 ubiquitin ligase. However, direct 
proof of this will require in vitro ubiquitination assays. Furthermore, our results indicate 
that NOXA levels might also be controlled at a post-translational level by MARCH5, and 
thus NOXA might also be a MARCH5 substrate. Again, whether this is direct or indirect 
will require in vitro studies; interpretation of these studies is complicated by the fact that 
NOXA stability can be regulated in an ubiquitin-independent manner46. Our finding that 
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MCL1 stabilization requires a physical interaction between NOXA and MCL1 itself 
suggests that a NOXA/MCL1/MARCH5 termolecular complex is present at some stage 
during the ubiquitination of MCL1. However, the precise mechanism by which NOXA 
itself is regulated by MARCH5 as well as its importance in mediating the ubiquitination of 
MCL1 warrants further study. 
 
 
 
 
Figure 4.1. MARCH5, MCL1 and NOXA co-regulation 
MARCH5 is the key regulator of a MCL1/NOXA complex through the 
ubiquitination of MCL1 in a NOXA-dependent manner.  
 
 
The terminal effectors of ABT-737-induced apoptosis are BAX and BAK. Both proteins 
form oligomers on the mitochondrial outer membrane in response to diverse apoptotic 
stimuli, thereby triggering the release of apoptogenic factors from mitochondria52.  
Here, we found that sensitization to ABT-737 upon MARCH5 loss was dependent on 
BAX, but not BAK. The activity of BAX and BAK is held in check by the anti-apoptotic 
proteins BCL2, BCLXL, and MCL1 and this interaction is disrupted upon upregulation of 
pro-apoptotic PUMA, BIM and NOXA26. In this context, the MARCH5-dependent 
upregulation of NOXA could serve to disrupt MCL1-BAX/BAK interactions thereby 
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sensitizing to apoptosis; although BAK was dispensable for this response. This is 
consistent with prior studies demonstrating that BAK is dispensable for the response to 
ABT-737 in the HCT116 cell line172.  
Given our findings, we propose a model for the role of MARCH5 in regulation of BH3 
protein-dependent apoptosis (Fig. 4.2). Under steady state conditions, MARCH5 is 
required to maintain an MCL1/NOXA ratio compatible with viability. This requires 
MARCH5 E3 ligase activity, and is NOXA-dependent. The loss of MARCH5 disrupts this 
balance and causes concomitant up-regulation of MCL1 and NOXA. However, MARCH5 
depletion alone is not lethal in these cells. This could be attributed to the presence of the 
other anti-apoptotic proteins (i.e., BCL2 and BCLXL), which protect from apoptosis even 
when MCL1 is neutralized.  The increase in NOXA serves to inhibit MCL1’s anti-
apoptotic activity, thereby allowing for the activation of BAX and sensitization to 
apoptosis upon administration of ABT-737 or other selective BH3 mimetics. 
Whether the MARCH5/NOXA/MCL1 axis also modulates the sensitivity to other 
chemotherapeutics remains to be determined. The levels of NOXA and MCL1 are critical 
determinants of the sensitivity to DNA-damaging agents such as cisplatin in solid 
tumors173. It would be of interest to assess how the activation of the NOXA/MCL1 axis 
through the loss of MARCH5 could modulate the sensitivity to these chemotherapeutics.  
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Figure 4.2. Proposed working model 
MARCH5 is a key regulator of a MCL1/NOXA complex under steady-state 
conditions. The loss of MARCH5 leads to a co-stabilization of both NOXA and 
MCL1. The stoichiometric shift in levels of NOXA to MCL1 functionally inhibit 
MCL1, thereby freeing the downstream effector protein BAX to mediate apoptosis. 
This process cumulatively serves as a “priming” mechanism and additional stress 
stimuli are required to trigger cell death. 
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(ii) MARCH5 chemical and genetic synthetic lethality 
WEHI-539, a BCLXL-selective inhibitor, had no effect on HCT116 cell viability when 
given as a single agent, but was synthetic lethal with MARCH5 loss. This phenocopies the 
effect observed when MCL1-null cells are treated with WEHI-539, as cells in which 
MCL1 is functionally inactivated rely on BCLXL for survival49,62 . Together, these data 
provide further evidence that the concomitant upregulation of NOXA with MCL1 
following MARCH5 loss is a ‘priming event’ for apoptosis, most likely due to functional 
inactivation of MCL1 through the concomitant upregulation of NOXA.  
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Figure 4.3. BCLXL protects against apoptosis once MCL1 is neutralized 
The loss of MARCH5 leads to increase in NOXA, which binds and functionally 
inhibits MCL1. Under these conditions, the presence of BCLXL protects cells 
against apoptosis. Therefore, dual inhibition of MCL1 and BCLXL is required to 
induce cell death. 
 
 
On the other hand the loss of MARCH5 did not sensitize cells to the BCL2-specific 
inhibitor, ABT-199. This suggests that MCL1 and BCLXL are the critical determinants of 
sensitization to cell death in our experimental setting. The concomitant loss of MARCH5 
and MCL1 displays synthetic lethality in MCL1-dependent breast cancers. This provides 
further evidence that targeting MCL1 both with MCL1 specific inhibitors and through 
MARCH5 depletion would be effective in tumors with high MCL1 levels.  
 
Our experiments have been conducted using a limited number of breast cancer cell lines. 
Therefore, testing this hypothesis in a larger panel of MCL1-dependent cancer cell lines 
from different tissue types would provide valuable insight into the efficacy of targeting 
MCL1 and MARCH5 in a broader context. Certain c-MYC-driven mouse lymphomas also 
show dependency on MCL1 for growth174. These mouse models could also be employed to 
validate the in vivo efficacy of MARCH5 and/or MCL1 inhibition.  
 
In addition to regulating the MCL1/NOXA axis, the loss of MARCH5 also led to 
transcriptional upregulation of the p53 targets p21 and PUMA. This suggests that there 
may be some form of mitochondria to nucleus communication. This could be a result of 
disruption in mitochondrial homeostasis upon MARCH5 loss and an initiation of a 
retrograde signaling response which is discussed below. 
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MARCH5 and mitochondrial retrograde signaling 
Mitochondrial retrograde signaling is the process of signal transduction from mitochondria 
to the nucleus to co-ordinate transcriptional responses. The retrograde signaling response 
in yeast is induced in response to altered metabolic states, while in mammalian cells is 
associated with changes in Ca2+ dynamics within the mitochondrial compartment. Other 
factors such as oxidative stress, mitochondrial DNA damage, and disruptions in 
mitochondrial membrane potential are also associated with retrograde signaling. This 
signaling activity ensures that cells can rapidly adapt to both internal and external 
environmental changes3,175.  
In the present study, the transcriptional upregulation of p53 targets was accompanied by 
collapse of mitochondria around the perinuclear region as well as loss of mitochondrial 
membrane potential. This type of stress could explain the stabilization and activation of 
p53 we observed following MARCH5 depletion176. It has been also been demonstrated that 
MARCH5 mediates mitochondrial-endoplasmic reticulum contacts through MFN2, and 
that disruption of these interactions lead to defective uptake of calcium from the ER to 
mitochondria137. It is possible that these changes could contribute to the retrograde 
activation of p53.  
 
Moreover, MARCH5-mediated sensitization to BH3 mimetics is partially p53-dependent. 
Thus, it is likely that MARCH5 loss lowers the threshold for apoptosis through both 
induction of mitochondrial stress and subsequent stress-related transcriptional changes as 
well as through altering protein-protein interactions at the mitochondria that allow for 
regulation of the MCL1/NOXA axis. NOXA, a p53 target, was a key determinant of ABT-
737 sensitivity. However, there was no significant change in NOXA mRNA following loss 
of MARCH5. We infer that the presence of p53 sets the basal level of NOXA, and that this 
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in turn will determine the absolute level of NOXA protein that is stabilized following loss 
of MARCH5. 
 
p53 was also required for maximal sensitization to ABT-737, it was dispensable for the 
synthetic lethal interaction between MARCH5 and MCL1. This is supported by 
experiments with MDA-MB-468 and MDA-MB-231: both these lines carry mutant p53, 
and were not sensitized to ABT-737 by MARCH5 knockdown, yet MCL1/MARCH5 
synthetic lethality was retained in MCL1-dependent MDA-MB-468.  Together, these data 
suggest that MARCH5 loss requires p53 for maximal sensitization to BH3 mimetics; 
however, factors beyond p53 (including MCL1 dependency as we show here) determine 
the intrinsic cellular sensitivity to depletion of MARCH5 
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Figure 4.4. Alterations in mitochondrial morphology upon MARCH5 loss could 
activate retrograde signaling responses 
The collapse of the mitochondrial network, loss of membrane potential and 
production of ROS observed upon depletion of MARCH5 could serve as a trigger 
for retrograde signaling from the mitochondria to the nucleus to activate stress-
related signaling pathways. 
 
Targeting MARCH5 in diseases 
(i) MARCH5 and cancer 
The present study has demonstrated that MARCH5 has an anti-apoptotic role in cancer 
cells. A survey of the COSMIC database indicates that MARCH5 mRNA is overexpressed 
in a restricted set of tumor types. However, the frequency of MARCH5 mutations in 
primary tumor samples and in tumor cell lines is low. Thus it can be inferred that 
MARCH5 does not necessarily fall into the class of traditional oncogenes but is still 
important for cancer cell survival during tumorigenesis or following treatment with 
therapeutic compounds. Consistent with this hypothesis, we found that MARCH5 
expression contributed to an 8-gene index that correlated with sensitivity to ABT-263 
(Navitoclax) in hematological malignancies. Indeed, its contribution was as significant as 
that of MCL1, a well-validated determinant of sensitivity to BH3 mimetics.  
 
Due to low sample sizes in the publically available databases, we were unable to extend 
our analyses to other tissue types. Therefore, further in vivo studies with appropriate tumor 
models are now required to determine whether targeted inhibition of MARCH5 will have a 
therapeutic benefit in cancer. As with all cancer targets, this is likely to depend on the 
precise genetic 
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makeup of individual tumors. Furthermore (as recently reported for MCL1 in the case 
of triple-negative breast cancer177), predictive signatures should 
additionally take into account not only mRNA expression, but also protein levels of 
MARCH5 and BCL-2 family members. 
The MARCH5-dependent sensitization to BH3 mimetics was strictly p53-dependent as this 
effect was attenuated in cell lines lacking p53 or harboring mutant p53. Thus a 
combination of factors must be taken into account while potentially targeting MARCH5 
for therapeutic purposes. It is probable that MARCH5 loss requires p53 for sensitization to 
certain chemotherapeutics; however the subset of tumors that are MCL1-driven could be 
targeted through the combined depletion of MCL1 and MARCH5.  
Breakthroughs in the design of selective MCL1 inhibitors indicate that direct targeting 
of this oncogene to induce cell death is now possible. Current data indicate that 
these compounds are effective in MCL1-dependent tumors, but have variable results 
in other cell lines157. Observations in the present study indicate that combined treatment 
with high doses of ABT-737 and A1210477 induce cell death in HCT116, but that this 
was no more effective than a combination of ABT-737 and MARCH5 knockdown. 
Together, these data clearly indicate that targeting MARCH5 will be particularly 
effective in combination with broad spectrum BH3 mimetics, or with the next 
generation of MCL1-selective antagonists. 
Further studies are required in order to determine the feasibility and efficacy of 
therapeutically targeting MARCH5 in cancer. The targeting of E3 ubiquitin ligases for 
cancer therapeutics is still at an early stage. There is a clear need for development of 
specific E3 ligase inhibitors, since many of them play critical roles in cancer development 
and progression. The general proteasome inhibitor, Velcade (Bortezomib) is an FDA-
approved compound that targets the ubiquitin-proteasome system178. In addition, the 
possibility of inhibiting SCF cullin-RING ligase with small molecules has been 
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demonstrated in chemical screens.  MLN4924, a small molecule inhibitor of NEDD8-
activating enzyme also has potential to be developed as a novel class of anti-cancer agents 
by restricting the neddylation of the SCF complex179. The challenge of targeting ubiquitin 
ligases lies in their extended flat surfaces, which disfavours the binding of small 
molecules180. Thus, identification of pathways regulated by specific E3 ligases or their 
substrates becomes crucial. This would offer an indirect route to target and inhibit 
biological function(s) of the ligase. 
In line with above strategies, in depth studies into additional MARCH5 substrates as well 
as upstream regulators of MARCH5 expression in tumor cells would provide additional 
strategies by which this ligase could be potentially inhibited. 
 
(ii) MARCH5 and neurodegenerative disorders 
Given the roles of MARCH5 in apoptotic signaling and maintenance of mitochondrial 
homeostasis, it is conceivable that MARCH5 could play a role in the context of 
neurological disorders. For example, the accumulation of dysfunctional mitochondria, 
defective mitophagy (i.e., clearance of damaged mitochondria), increased ROS production 
and cellular stress all contribute to the development and/or progression of 
neurodegenerative disorders such as Parkinson’s disease128,132,164.  
In contrast to its pro-survival role in tumor cells, however, MARCH5 appears to 
exacerbate neurodegenerative stress via disrupting mitochondrial membrane potential and 
increasing the levels of ROS181,182. Thus MARCH5 appears to possess opposing roles in 
different tissue types. This “yin-yang” phenomenon has been described in the functions of 
proteins such as Notch, which can behave as an oncogene or tumor suppressor depending 
on the cellular context183. 
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Interestingly, the loss of MARCH5 in cancer cells led to perinuclear accumulation of 
mitochondria, which is reminiscent of the phenotype observed upon the treatment of 
CCCP. This phenotype has been associated with the induction of mitophagy through 
recruitment of PARKIN164. Thus, it would be interesting to observe whether the loss of 
MARCH5 could also trigger the translocation of PARKIN to mitochondria. MARCH5 has 
been identified as a PARKIN substrate in a proteomic screen following induction of 
mitophagy in HCT116 cells with CCCP, again indicative of a link with the mitophagy 
pathway131. Together, these data suggest that further studies are warranted to determine the 
role of MARCH5 in mitophagy and neurodegeneration.  
 
FUTURE DIRECTIONS 
Apart from activation of the p53 pathway, there may be global changes in transcription in 
response to the perturbation of MARCH5. Further studies are thus warranted in order to 
gain a better understanding of how MARCH5 disruption alters gene expression. RNA-seq 
in the presence and absence of MARCH5, or with the expression of MARCH5 functional 
mutants will be valuable in this regard. Genome-wide synthetic lethal screens would also 
allow for discovery of specific pathways regulated by MARCH5.  From a therapeutic 
standpoint, chemical screens would enable the identification of compounds that sensitize 
cancer cells to cell death in combination with the loss of MARCH5.  
 
The effects of the somatic mutations described in cancer databases on MARCH5 function 
remain unclear. Data presented herein show that the D202Y and D202G mutants promote 
hyperfusion of the mitochondrial network. This suggests that these could be gain-of-
function mutations as certain cancers rely on hyperfused mitochondria to increase 
metabolic rates184. This however requires further study to clearly define the contributions 
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of these mutations to tumorigenesis. A proteomic approach could also be employed to 
identify proteins that differentially associate with the wild-type and mutant forms of 
MARCH5. This in turn would facilitate the functional characterization of these mutants in 
cancer.  
The ubiquitination process occurs in a reversible manner. Deubiquitinating enzymes 
(DUBS) are a family of proteases that cleave ubiquitin from proteins.  However, the 
precise mechanisms by which deubiquitinating enzymes (DUBS) regulate mitochondrial 
signaling events is largely unknown. USP30 and USP35 are two DUBS that have displayed 
mitochondrial specific localization and regulate mitophagy by deubiquitinating PARKIN 
substrates185. Intriguingly the depletion of USP30 sensitized cancer cells to the BH3 
mimetic ABT-737186; indicative of a potential role of USP30 in the regulation of 
mitochondrial cell death. Further studies are warranted in order to determine whether 
MARCH5 and these two mitochondrial DUBS possess common substrates and function 
together to regulate the cell death process. 
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APPENDIX I 
 
  WT-p53 (221) WT-p53 Blood (41) 
Predictor Estimate SE pValue Estimate SE pValue 
(Intercept) 2.17 0.24 ** 1.67 1.87 0.39 
MARCH5 -0.17 0.13 0.21 5.54 2.11 * 
MCL1 0.42 0.22 0.06 6.62 2.44 * 
BIM 0.14 0.21 0.49 0.68 0.83 0.43 
BAX -0.65 0.15 ** -3.07 0.87 * 
HUWE1 -0.59 0.20 * -1.92 1.56 0.25 
BAK1 0.40 0.20 0.05 -8.85 2.79 * 
NOXA -0.81 0.17 ** -0.68 1.70 0.70 
BCLXL 0.38 0.21 0.07 2.28 2.52 0.39 
MARCH5:BAK1 -0.40 0.13 *       
MCL1:BAX 0.41 0.17 * -3.46 1.57 0.05 
MCL1:BAK1 -0.22 0.16 0.15 4.58 1.30 * 
BAK1:BCLXL -0.36 0.18 * 2.86 1.90 0.16 
BIM:BAK1       5.35 1.72 * 
HUWE1:BCLXL 0.51 0.19 * -4.61 2.77 0.13 
BAX:BAK1       -1.38 0.92 0.17 
BIM:NOXA             
MARCH5:BAX       -1.80 0.74 * 
MARCH5:BCLXL       -1.97 1.46 0.21 
BIM:BAX -0.38 0.17 * -1.55 0.97 0.14 
BAK1:NOXA       4.79 1.43 * 
BIM:BCLXL       -6.41 2.35 * 
MARCH5:MCL1       1.01 0.74 0.20 
MCL1:BCLXL       4.03 1.81 * 
MARCH5:NOXA 0.20 0.15 0.17 -3.20 1.25 * 
MCL1:NOXA -0.38 0.19 *       
BAX:BCLXL       1.91 1.37 0.19 
BAX:HUWE1       3.62 1.54 * 
BIM:HUWE1       5.81 1.55 * 
MARCH5:BIM       0.78 0.99 0.45 
MARCH5:HUWE1       3.06 1.26 * 
MCL1:BIM 
   
-3.60 1.39 * 
NOXA:BCLXL    -5.08 1.69 * 
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Figure 5.1. Tabulation of results of multiple regression analysis 
Results of optimized multiple linear regression analysis for all cell lines with wild 
type p53 (n = 221), and the wild type p53 blood subset. Each row shows the 
estimate value (i.e., the unit change in IC50) that is predicted for every unit 
increase in expression of the particular gene. SE, standard error of the estimate 
value. p values indicate whether each gene (or pairwise interaction) was deemed 
significant. An empty row indicates that the interaction was not considered 
significant in the relevant subset. Pairwise interactions discussed in Chapter 3 are 
highlighted in yellow. 
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APPENDIX II 
Regulation of MARCH5 through the AKT pathway 
 
INTRODUCTION 
The activation of oncogenes often leads to the re-programming of mitochondrial function 
in order to facilitate tumor initiation or tumor maintenance. Chemotherapeutic resistance 
can also emerge due to oncogene-induced rewiring of mitochondria1,4,7. Thus, defining the 
key cytosolic and mitochondrial proteins that promote the re-programming of mitochondria 
is critical for the design of effective treatment strategies.  
 
Oncogenes known to reprogram mitochondria during tumorigenesis include, RAS, MYC, 
and AKT187,188,189.  These oncogenes can be activated via frank mutation, amplification, or 
deregulation of epigenetic control. However, they can also be activated indirectly via the 
loss of tumor suppressor protein function. A case in point is the activation of AKT that 
accompanies the loss of PTEN in many tumors190. 
 
Given that MARCH5 has a pro-survival role in cancer cells, we hypothesized that 
it might exhibit functional interactions with oncogenic signaling pathways. We initially 
focused our attention on the PTEN/AKT axis, as its deregulation has direct impacts on 
mitochondrial function191. 
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RESULTS 
 
Loss of PTEN is associated with increased MARCH5 expression 
A panel of breast cancer lines that differed in PTEN status was interrogated along with 
MCF10A isogenic lines that were PTEN hetero- or homozygous knockout. Fig. 6.1a shows 
that although  there was no direct relationship between the absolute level of PTEN protein 
and the level of MARCH5,  the specific loss of PTEN in genetically engineered MCF10A 
cells was associated with an increase in MARCH5 levels (compare lanes 1-3).  
Furthermore, MARCH5 levels were increased in 6/7 of a panel of human breast cancer cell 
lines compared to non-tumorigenic MCF10A (compare lane 1 to lanes 4–10). MARCH5 
upregulation is post-translational, since the level of MARCH5 mRNA does not correlate 
with the absolute amount of MARCH5 protein (Fig. 6.1b).  
 
 
 
. 
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Figure 6.1. PTEN loss is associated with increased MARCH5 expression 
(a) Whole cell lysates from the MCF10A isogenics and a panel of breast cancer lines 
were subjected to SDS-PAGE and immunoblotted with the indicated antibodies. 
(b)  PTEN and MARCH5 levels in MCF10A isogenic lines and breast cancer cell lines 
were assessed using qRT-PCR. 18S mRNA was used as loading control. 
 
 
Chemical inhibition of the AKT pathway leads to destabilization of 
MARCH5 protein 
Since AKT is activated upon loss of PTEN, we reasoned that AKT might regulate 
MARCH5 steady state levels. To test this, MCF10A isogenic cells were treated with SH6, 
a small molecule inhibitor of AKT.  The phosphorylation of AKT at S473 and T308 
activates the protein and thus measuring the phosphorylated forms of AKT is used a 
readout of AKT activation192 . However we were unable to detect AKT or its 
phosphorylated forms in the MCF10A cell lines, probably due to low basal expression.  
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Strikingly, the compound downregulated MARCH5 protein but did not affect MARCH5 
mRNA (Fig. 6.2a). Importantly, the levels of TOMM20 were unchanged under these 
conditions, indicating that the SH6 inhibitor does not have a ‘global’ effect on MOM 
proteins. This demonstrated that the inhibition of AKT signaling was specifically 
destabilizing MARCH5. 
 
Interestingly, scanning of the MARCH5 amino acid sequence reveals a highly conserved 
AKT phosphorylation site within the functionally important RING domain of the protein. 
Our prior results demonstrate that the RING domain is critical for regulating MARCH5 
stability, and that mutations in this domain lead to stabilization of the protein. Thus, it 
would be of interest to assess how phosphorylation events within this domain determine 
the auto-regulation of MARCH5 levels. 
 
124 
 
a
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
b 
 
Figure 6.2. Inhibition of AKT destabilizes MARCH5 protein 
(a) MCF10A isogenic cell lines were treated with 10 μM of SH6 inhibitor for the 
indicated timepoints. Whole cell lysates were then harvested and subjected to SDS-
PAGE and immunoblotted with the indicated antibodies. 
(b) Scanning of phosphorylation sites on MARCH5 using the NetPhosK server 
revealed a potential AKT phosphorylation site. 
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DISCUSSION 
The upregulation of MARCH5 observed in the engineered MCF10A and breast cancer cell 
line panel is likely associated with the re-wiring of cell signaling networks upon PTEN loss 
such as the hyper-activation of the AKT pathway. Chemical inhibition of AKT signaling 
also led to destabilization of MARCH5 protein suggesting that AKT is a potential 
upstream regulator of MARCH5 expression. 
 
Interestingly, the predicted AKT phosphorylation site in MARCH5 falls within the 
important functional RING domain. Thus, the phosphorylation of MARCH5 could serve as 
an important regulatory mechanism. In this regard, similar phosphorylation-dependent 
regulatory events have been reported for the MDM2 E3 ligase.  The phosphorylation of 
MDM2 near the C terminus inhibits RING domain oligomerization by the ATM kinase results in 
p53 stabilization after DNA damage193. The TRAF2 E3 ligase is also phosphorylated within its 
RING domain and this in turn induces NF-κB signaling194. 
 
Clearly, further studies are required to fully understand the mechanism by which AKT 
regulates MARCH5. In this regard, generation of phospho-mutants of MARCH5 will 
provide further insight into whether AKT (or indeed other kinases) control MARCH5 
stability and/or function.  
 
In addition, the AKT family is comprised of three different homologous isoforms. Studies 
in AKT isoform-specific knockout mice have shown that the different isoforms possess 
distinct functions195. Thus RNAi directed against specific isoforms would provide an 
indication of which isoform modulates MARCH5 levels and the significance of this 
regulation.  
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The functional interaction between MARCH5 and other oncogenes or tumor suppressors 
remains unclear. A literature survey revealed that MARCH5 scored as a synthetic lethal hit 
with RAS in a functional genomics screen, although this was not followed up by the 
authors. Furthermore, MARCH5 is mutated or upregulated in several primary tumors that 
carry RAS mutations196.  
 
Thus it appears that MARCH5 could be regulated at different levels during the course of 
tumorigenesis. Having observed a pro-survival role for MARCH5 in cancer, it is critical to 
identify upstream regulators in order to devise potential therapeutic strategies to target 
MARCH5. Furthermore, identification of the upstream regulators or the oncogenes that 
depend on MARCH5 would be useful for potential patient stratification if MARCH5 
becomes a fully validated oncology target. 
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MATERIALS AND METHODS 
Cell Culture  
MCF10A WT and isogenic cell lines were cultured in DMEM/HAM’s F12 supplemented 
with 5% horse serum, 4 mM L-glutamine, 100 U/ml penicillin, and 100 U/ml of 
streptomycin, 20 ng/ml EGF, 0.5 mg/ml hydrocortisone, 100ng/ml cholera toxin and 
10μg/ml insulin in a humidified atmosphere of 5% CO2 at 37°C. Cells were passaged prior 
to reaching full confluency for general maintenance. DMEM, HAM’s F12, L-glutamine, 
penicillin and streptomycin were purchased from Lonza (Basel, Switzerland). EGF was 
purchased from Peprotech (UK), hydrocortisone, cholera toxin and insulin were purchased 
from Sigma-Aldrich  (St. Louis, MO, USA). Breast cancer cell line pellets were provided 
by the IEO tissue culture facility. 
 
Compound treatments 
SH6 inhibitor was purchased from Calbiochem and used at a concentration of 10 μM for 
48 h. 
 
Western blot and antibodies 
Cells were lyzed in 0.5% NP-40 lysis buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 150 
mM NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 
10 mM NaF and Complete Mini Protease Inhibitors (Roche, Nutley, NJ, USA), at 
4°C for 30 min. Following SDS-PAGE electrophoresis, proteins were transferred 
onto nitrocellulose membranes. Membranes were incubated with the following 
antibodies: anti-MARCH5 (gifted by Dr. Nakamura, Tokyo Institute of Technology), anti-
PTEN (Cell Signaling Technologies) , anti-vinculin (Sigma-Aldrich) and anti-TOMM20 
(Santa Cruz Biotechnologies). 
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RT-qPCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and complementary DNA 
(cDNA) was synthesized using the ImProm-II Reverse Transcription System 
(Promega). Ten nanograms cDNA was used per PCR reaction with SYBR Green 
PCR Master Mix (Applied Biosystems, ABI) and quantified on the BIORAD CFX96 
Real Time System. Fold changes in mRNA expression was quantified using the Δ-ΔCt 
algorithm with 18S ribosomal RNA as loading control. qPCR primers are tabulated below. 
 
  Forward (5'-3') Reverse (5'-3') 
18S GATTAAGTCCCTGCCCTTTGTACA GATCCGAGGGCCTCACTAAAC 
      
MARCHV GATGCTGGACAGAAGTTGCTGG CCACTCTGGCTGTACTGTTTCC 
      
PTEN AATGTTCAGTGGCGGAACTTGC ACATGAACTTGTCTTCCCGTCG 
      
 
 
Phosphorylation site prediction analysis 
MARCH5 phosphorylation site prediction was performed using the NetPhosK server- 
http://www.cbs.dtu.dk/services/NetPhosK/ as described by Blom et al., 2004197. 
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